



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/12, C07K 14/47, 14/705, 7/06, 16/18, A61K 31/70, 38/08, 35/14, 38/17, G01N 33/53</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/32769</b> <b>(43) International Publication Date:</b> 8 June 2000 (08.06.00)
<b>(21) International Application Number:</b> PCT/IB99/02018 <b>(22) International Filing Date:</b> 26 November 1999 (26.11.99) <b>(30) Priority Data:</b> 9826143.1 27 November 1998 (27.11.98) GB <b>(71) Applicant (for all designated States except US):</b> LUDWIG INSTITUTE FOR CANCER RESEARCH [US/US]; 605 Third Avenue, New York, NY 10158 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HUANG, Lan-Qing [BE/BE]; Ludwig Institute for Cancer Research, Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). VAN PEL, Aline [BE/BE]; Ludwig Institute for Cancer Research, Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). BRASSEUR, Francis [BE/BE]; Ludwig Institute for Cancer Research, Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). DE PLAEN, Etienne [BE/BE]; Ludwig Institute for Cancer Research, Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). BOON, Thierry [BE/BE]; Ludwig Institute for Cancer Research, Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE).		<b>(74) Agents:</b> WOODWARD, John, Calvin et al.; Venner, Shipley & Co., 20 Little Britain, London EC1A 7DH (GB).  <b>(81) Designated States:</b> AU, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> TUMOUR REJECTION ANTIGENS  <b>(57) Abstract</b>  Polypeptides comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## Tumour rejection antigens

### Description

This invention relates to polypeptides and proteins expressed in tumour cells and to  
5 nucleic acid molecules coding for such polypeptides and proteins. The invention  
also relates to expression vectors and host cells for expressing such polypeptides  
and proteins, and to polypeptide-binding agents which selectively bind or are  
specific for such polypeptides or proteins. The invention further relates to methods  
of treating and diagnosing disease, preferably cancers, using such polypeptides,  
10 proteins, nucleic acids, polypeptide-binding agents, expression vectors or  
transformed host cells.

The phenotypic changes which distinguish a tumour cell from its normal  
counterpart are often the result of one or more changes to the genome of the cell.  
15 The genes which are expressed in tumour cells, but not in normal counterparts, can  
be termed "tumour specific" or "tumour associated" genes. These tumour specific  
or associated genes can be markers for the tumour phenotype.

The process by which the mammalian immune system recognises and reacts to  
20 foreign or alien materials is a complex one. An important facet of the system is the  
response of cytolytic T lymphocytes (CTLs) or T cells. CTLs recognise and interact  
with complexes of cell surface molecules, referred to as human leukocyte antigens  
("HLA"), or major histocompatibility complex molecules ("MHC" molecules), and  
other peptides derived from larger molecules from within the cells carrying the  
25 HLA/MHC complexes. See, in this regard, Male et al., Advanced Immunology (J.P.  
Lipincott Company, 1987), especially chapters 6-10, and C.A. Janeway et al.  
Immuno Biology third ed. (Current Biology Ltd. 1997). The interaction of T cells  
and complexes of HLA/peptide is restricted, requiring a T cell specific for a  
particular combination of an HLA molecule and a peptide. If a specific CTL is not  
30 present, there is no T cell response even if its partner complex is present. Similarly,  
there is no response if the specific complex is absent, but the CTL is present. The  
mechanism is involved in the immune system's response to foreign materials, in  
autoimmune pathologies, and in responses to cellular abnormalities. Much work has

focused on the mechanisms by which proteins are processed into the HLA binding peptides. See, in this regard, Barinaga, *Science* 257:880, 1992; Fremont et al., *Science* 257:919, 1992; Matsumura et al., *Science* 257:927, 1992; Latron et al., *Science* 257:964, 1992.

5

The mechanism by which T cells recognise cellular abnormalities has also been implicated in cancer. A number of families of genes which are processed into peptides that are presented as HLA/peptide complexes on the surface of tumour cells, with the result that the cells can be lysed by specific CTLs, have been  
10 discovered. These genes are said to code for "tumour rejection antigen precursors" or "TRAP" molecules, and the peptides derived therefrom that complex with HLA are referred to as "tumour rejection antigens" or "TRAs". Intensive efforts have been made in this field and a wealth of human tumour rejection antigens (both TRAPs and TRAs) which are recognised by T cells have been identified (Van den  
15 Eynde, B.J., and P. van der Bruggen, 1997, *Curr. Opin. Immunol.* 9:684.). Among them, a TRAP encoded by the gene *MAGE-1* was initially defined by cultivating blood lymphocytes of patient MZ2 in the presence of a melanoma cell line derived from the same patient. A panel of CTL clones was generated by mixed lymphocyte-tumour cell culture (MLTC) techniques, and one of these clones recognised a  
20 nonapeptide TRA derived from the *MAGE-1* TRAP, which is presented by HLA-A1 (van der Bruggen, P., C. et al., 1991, *Science (Wash. DC)*. 254:1643-1647; Traversari, C., et al., 1992, *J. Exp. Med.* 176:1453-1457 and WO92/20356). It was found later that *MAGE-1* belongs to a family of at least seventeen related genes, namely *MAGE-1* to -12 (now named *MAGE-A1* to -A12) (De Plaen, E., et al., 1994,  
25 *Immunogenetics*. 40:360-369.), *MAGE-B1* to -B4 (Muscatelli, F., et al., 1995, *Proc. Natl. Acad. Sci. USA*. 92:4987-4991; Dabovic, B., et al., 1995, *Mammalian Genome*. 6:571-580; and Lurquin, C., et al., 1997, *Genomics*. 46:397-408), and *MAGE-C1* (Lucas, S., et al., 1998, *Cancer Res.* 58:743-752).

30 Genes of this family are expressed in various tumours of different histological types, but are completely silent in normal tissues with the exception of testis and placenta (De Plaen, E., et al., 1994, *Immunogenetics*. 40:360-369; Dabovic, B., et al., 1995, *Mammalian Genome*. 6:571-580; Lurquin, C., et al., 1997, *Genomics*. 46:397-408; and

Lucas, S., et al., 1998, *Cancer Res.* 58:743-752.). However, as testicular germ cells and placental trophoblasts do not express MHC class 1 molecules (Haas, G.G.Jr., et al., 1988, *Am. J. Reprod. Immunol. Microbiol.* 18:47-51.), gene expression in these tissues should not lead to antigen expression. Indeed, immunisation of male mice  
5 with an antigen encoded by mouse P1A gene, which has the same expression pattern as human *MAGE* gene, i.e., expressed in tumours, testis and placenta, but silent in other normal tissues, produced strong P1A-specific CTL responses that did not cause testis inflammation or alteration of fertility (Uyttenhove, C., C. et al., 1997, *Int. J. Cancer.* 70:349-356.). Antigens encoded by *MAGE* genes are, therefore,  
10 suitable candidates for vaccine-based immunotherapy of cancers and as markers for providing a means of identifying a cell as a so treatable tumour cell.

So far, however, it has only proven possible to identify TRAs encoded by *MAGE-A1*, *-A3* and *-A6* by using autologous CTLs derived from mixed lymphocyte-tumour cell cultures (MLTC) and previous gene expression assays have suggested  
15 that *MAGE-A10* was expressed in tumours at a level that was too low to be sufficient for CTL recognition. All these CTLs were generated from only one patient, MZ2 (Traversari, C., et al., 1992, *J. Exp. Med.* 176:1453-1457; van der Bruggen, P., et al., 1994, *Eur. J. Immunol.* 24:2134-2140; Gaugler, B., et al., 1994,  
20 *Exp. Med.* 179:921-930; De Plaen, E., et al., 1994, *Immunogenetics.* 40:360-369; and P. van der Bruggen, unpublished data). However, the inventors have now been able to obtain autologous CTL clones from another melanoma patient, LB 1751, which recognize and have allowed the identification of hitherto unknown HLA-A2.1-presented TRAs encoded by *MAGE-A10* and *MAGE-A8*.

25 Accordingly, the present invention provides a polypeptide comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 (Figure 7) or SEQ. ID. NO. 2 (Figure 8) which has an ability to complex with an MHC molecule type HLA-A2, preferably HLA-A2.1. Polypeptides in accordance with the invention can comprise  
30 unbroken sequences of amino acids from SEQ. ID. NO. 1 or 2 which have an ability to elicit an immune response from human lymphocytes.

Polypeptides in accordance with the invention can comprise nonapeptides having an unbroken sequence of amino acids from SEQ. ID. NO. 1, or 2, wherein the amino acid adjacent to the N-terminal amino acid is L or M, preferably L, and the C-terminal amino acid is L, V or I, preferably L. Preferably, the amino acid in position 3 is Y, and/or the amino acid in position 4 is D, and/or the amino acid in position 5 is G, and/or the amino acid in position 7 is E, and/or the amino acid in position 8 is H. The amino acid positions are numbered from the N-terminal to the C-terminal, with the N-terminal amino acid in position 1. The polypeptides described above are preferably capable of complexing with a MHC molecule type HLA-A2, and preferably HLA-A2.1.

The invention, preferably, does not encompass nonapeptides having the amino acid sequences FLLFKYQMK (SEQ. ID. NO. 48), FIEGYCTPE (SEQ. ID. NO. 49), and GLELAQAPL (SEQ. ID. NO. 50).

15

The inventive polypeptide alternatively can be a decapeptide comprising a nonapeptide as defined above and, preferably, an unbroken sequence of amino acids from SEQ. ID. NO. 1, or 2. In preferred embodiments the nonapeptide has the amino acid sequence GLYDGMEHL (SEQ. ID. NO. 42) or GLYDGREHS (SEQ. ID. NO. 43), preferably GLYDGMEHL (SEQ. ID. NO. 42). In embodiments, the decapeptide can have the amino acid sequence GLYDGMEHLI (SEQ. ID. NO. 44) or GLYDGREHSV (SEQ. ID. NO. 45), preferably GLYDGMEHLI (SEQ. ID. NO. 44).

In a further aspect, the present invention comprises a polypeptide or protein of up to about 93 amino acids in length which comprises a nonapeptide or a decapeptide as defined above. Such a polypeptide or protein can comprise or consist of an unbroken sequence of amino acids from SEQ. ID. NO. 1, or 2, preferably SEQ. ID. NO. 1.

30

It is preferred that polypeptides in accordance with the present invention are capable of eliciting an immune response from human lymphocytes, preferably when complexed with an MHC molecule type HLA-A2, preferably HLA-A2.1. The

immune response is preferably a cytolytic response from human T-lymphocytes, preferably CD8 T-cells.

5 In a further aspect, the present invention provides a polypeptide or protein comprising a polypeptide as defined above, wherein the amino acid sequence of said polypeptide or protein is not either of the complete sequences set out in SEQ. ID. NOs. 1 and 2, or that coded for by nucleotides 334-918 of SEQ. ID. NO. 7 (Figure 13).

10 The invention also extends to polypeptides or proteins which are functionally equivalent homologues to any of the above defined polypeptides or proteins, but with the proviso that the amino acid sequence of said polypeptide or protein is not an entire sequence as set out in either of SEQ. ID. NOs. 1 and 2, or that coded for by nucleotides 334-918 of SEQ. ID. No. 7. In embodiments of the invention, the  
15 polypeptides can be complexed with an MHC molecule type HLA-A2, preferably HLA-A2.1.

In another aspect, the present invention provides nucleic acid molecules, each comprising a nucleotide sequence coding for a polypeptide or protein in accordance  
20 with previously defined aspects of the invention or a complimentary nucleotide sequence, wherein said nucleotide sequence is not an entire sequence as set out in any of SEQ. ID. NO. 3 (Figure 9), SEQ. ID. NO. 4 (Figures 10a and 10b), SEQ. ID. NO. 5 (Figures 11a and 11b), SEQ. ID. NO. 6 (Figure 12) and SEQ. ID. NO. 7 (Figure 13). Such a nucleic acid molecule can comprise an unbroken sequence of  
25 nucleotides from SEQ. ID. NO. 3, 4 or 5, or a complimentary sequence, or an RNA transcript of said nucleic acid molecule.

In a preferred embodiment, such a nucleic acid molecule can encode a plurality of epitopes or a polytope.

30

In a further aspect, the present invention provides expression vectors, each comprising a nucleic acid molecule as previously defined, operably linked to a promoter. Expression vectors in accordance with the invention can comprise a

nucleotide sequence coding for an MHC molecule type HLA-A2, preferably HLA-A2.1, a cytokine or a co-stimulatory molecule, or a bacterial or viral genome or a portion thereof.

5 In an additional aspect, the present invention relates to host cells, each transformed or transfected with an expression vector in accordance with the invention. Such a host cell can be transformed or transfected with an expression vector coding for an MHC molecule type HLA-A2, preferably HLA-A2.1, and/or a cytokine or a co-stimulatory molecule.

10

In a yet further aspect, the present invention provides polypeptide-binding agents, each of which can selectively bind or is specific for an isolated polypeptide or protein in accordance with the invention. A polypeptide-binding agent in accordance with the invention can comprise an antibody, preferably a monoclonal  
15 antibody or an antibody fragment specific for an isolated polypeptide in accordance with the invention. Preferably, such polypeptide-binding agents can selectively bind or are specific for a complex of a polypeptide in accordance with the invention and an MHC molecule type HLA-A2, preferably HLA-A2.1, but do not bind said major histocompatibility molecule alone. Further polypeptide-binding agents in  
20 accordance with the invention include CTLs and CTL clones which recognise and selectively lyse cells which carry a polypeptide in accordance with the invention complexed with an MHC molecule type HLA-A2, preferably HLA-A2.1.

In another aspect, the present invention relates to the use of a polypeptide or  
25 protein, isolated nucleic acid molecule, expression vector, host cell, or polypeptide-binding agent in accordance with the invention, in the therapy, prophylaxis, or diagnosis of disease and, preferably, of tumours. Thus, the invention also relates to pharmaceutical compositions for the prophylaxis, therapy or diagnosis of disease, preferably of tumours, comprising a polypeptide or protein, a nucleic acid molecule,  
30 an expression vector, a host cell, or a polypeptide-binding agent in accordance with the invention, optionally in admixture with a pharmaceutically acceptable carrier and optionally further comprising a major histocompatibility molecule type HLA-A2, preferably HLA-A2.1. Such pharmaceutical compositions can be employed as anti-



tumour vaccines. Optionally pharmaceutical compositions in accordance with the invention can include other TRAs or TRAPs, expression vectors or host cells expressing other TRAs or TRAPs, or polypeptide-binding agents specific for other TRAs or TRAPs. In another embodiment, pharmaceutical compositions in accordance with the invention can further comprise a co-stimulatory molecule.

In a preferred embodiment, a pharmaceutical composition in accordance with the invention comprises an antigen presenting cell (APC), preferably a dendritic cell, which has been pulsed with a polypeptide in accordance with the invention so as to present on its surface said peptide as a complex with a major histocompatibility molecule, HLA.

In another aspect, the present invention provides peptide-pulsed antigen presenting cells.

In a yet further aspect, the invention relates to a method of diagnosing disease, preferably cancer, comprising contacting a biological sample isolated from a subject with an agent that is specific for a polypeptide or protein in accordance with the invention, or a nucleic acid molecule in accordance with the invention and assaying for interaction between the agent and any of the polypeptide, protein or nucleic acid molecule in the sample as a determination of the disease. The polypeptide-binding agent employed in this aspect of the invention can be a polypeptide-binding agent in accordance with a previously described aspect of the invention.

The invention also relates to methods of producing cytolytic T-cell cultures reactive against tumour cells. Such a method can comprise steps of removing a lymphocyte sample from an individual and then culturing the lymphocyte sample with a polypeptide or protein in accordance with the invention, an expression vector in accordance with the invention, or a host cell in accordance with the invention. Products comprising cytolytic T-cells reactive against a tumour cell expressing an antigen comprising a polypeptide or protein in accordance with the invention, can be used in the prophylaxis, therapy or diagnosis of disease preferably of tumours,

are also encompassed in the present invention, particularly when obtained or obtainable by the aforementioned method.

As set out above, the present invention can involve the use of expression vectors to transform or transfect host cells and cell lines. Thus, a coding DNA sequence in accordance with the invention can be introduced into an expression vector suitable for directing expression of a polypeptide or protein in accordance with the invention (coded for by that DNA sequence) in a host cell. Suitable vectors include bacterial plasmids, phage DNA, cosmids, yeast plasmids and viral DNA, such as pox virus (e.g. vaccinia), retrovirus, baculovirus and adenovirus DNA. The procedure generally involves inserting a DNA sequence to be expressed into an appropriate restriction endonuclease site so that it is operably linked to a promoter for directing mRNA synthesis. A coding sequence and regulatory sequence, such as a promoter sequence, are considered to be "operably" linked when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequence. The resulting vector may then be employed to transform or transfect an appropriate host cell to cause that host cell to express the required polypeptide or protein. Appropriate host cells can be higher eukaryotic cells, such as mammalian cells and insect cells or can be lower eukaryotic cells, such as yeast cells, or prokaryotic cells, such as bacterial cells. Examples include E-coli, Bowes melanoma, CHO and COS cells. Selection of an appropriate host and the manner in which the vector is introduced into the host cell are matters within the knowledge of those skilled in the art. However appropriate techniques, cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described in Sambrook et al, Molecular Cloning, A Laboratory Manual, Second edition, Coldspring Harbour, NY, 1989.

Expression vectors in accordance with the invention can include a nucleic acid sequence coding for the HLA molecule that presents a particular polypeptide in accordance with the invention. Alternatively, the nucleic acid sequence coding for the HLA molecule can be contained within a separate expression vector within a host cell in accordance with the invention. In a situation where the vector contains both coding sequences, the single vector can be used to transfect the cell which

does not normally express either one. Where the coding sequence for the inventive polypeptide or protein and the HLA molecule which presents the former are contained on separate expression vectors, the expression vectors can be cotransfected. Sequences coding for polypeptides or proteins in accordance with the invention may be used alone, when, e.g. the host cell already expresses an HLA molecule which presents the TRA.

Preferred systems for mRNA expression in mammalian cells include the pRc/CMV (available from Invitrogen, Carlsbad, CA, USA) system that contains a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cells lines is the pCEP4 vector (Invitrogen), which contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 $\alpha$ , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (Nuc. Acids Res. 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (Mol. Cell. Biol. 16:4710-4716, 1996). A further preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (J. Clin. Invest. 90:626-630, 1992). The use of the adenovirus as an adeno-P1A recombinant is disclosed by Warnier et al: in Intradermal injection in mice for immunisation against P1A (Int. J. Cancer, 67:303-310, 1996).

As stated above, the invention can involve polypeptide-binding agents specific for or selective for polypeptides or proteins in accordance with the invention. An agent should be considered as "specific" for a particular polypeptide or protein if it is capable of interacting with that polypeptide or protein in a manner which can be distinguished from its interaction with other molecules in the context in which it is used. For example, such an agent may be capable of selectively binding to a relevant polypeptide or protein under the conditions prevalent in a particular assay. The term "contacting" means that a biological sample is placed in sufficient

proximity to an agent and under appropriate conditions of, for example, concentration, temperature, time, to allow the specific interaction between the agent and any polypeptide or protein for which it is specific, to take place. Appropriate conditions for contacting agents and biological samples are well known to those skilled in the art and are selected to facilitate the specific interaction between particular target molecules and specific agents. Polypeptide-binding agents can be used in this way in screening assays to detect the presence or absence of proteins or polypeptides in accordance with the invention and in purification protocols to isolate such proteins and polypeptides. Polypeptide-binding agents in accordance with the invention can be in the form of immobilised antibodies attached to a substrate and the inventive method of diagnosing disease can involve a conventional enzyme-linked immunosorbent assay (ELISA) carried out on a protein containing biological sample derived from a patient. Alternatively, the method can comprise a Western blot in which the agent is a labelled antibody and the biological sample comprises proteins derived from a patient and separated by electrophoresis on an SDS polyacrylamide gel. Polypeptide-binding agents can be used to selectively target drugs, toxins or other molecules to cancer cells which present polypeptides in accordance with the invention. In this manner, cells present in tumours which express polypeptides or proteins in accordance with the invention can be treated with cytotoxic compounds.

As stated, the invention can involve antibodies or fragment of antibodies having the ability to selectively bind to polypeptides or proteins in accordance with the invention. Such antibodies include polyclonal and monoclonal antibodies, prepared according to the conventional methodology.

The antibodies of the present invention can be prepared by any of a variety of methods, including administering protein, fragments of protein, cells expressing the protein or fragments thereof and the like to an animal to induce polyclonal antibodies. The production of monoclonal antibodies is according to techniques well known in the art. Such antibodies may be used for example to identify tissues expressing protein or to purify protein. Antibodies also may be coupled to specific labelling agents for imaging or to antitumour agents, including, but not limited to,

methotrexate, radioiodinated compounds, toxins such as ricin, other cystostatic or cytolytic drugs, and so forth. Antibodies prepared according to the invention also preferably are specific for the TRA/HLA complexes described herein.

5 Significantly, as is well known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark W.R. (1986) *The Experimental Foundations of Modern Immunology* Wiley & Sons, Inc., New York; Roitt, I. (1991) *Essential Immunology*, 7<sup>th</sup> Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for  
10 example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')<sub>2</sub> fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has  
15 been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different  
20 light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well known in the art, there are complementarity determining regions (CDRs), which directly interact with the  
25 epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in  
30 particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

It is now well established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of nonspecific or heterospecific antibodies while retaining the epitope specificity of the original antibody. This is most clearly manifested in the development and use of "humanised" antibodies which non-human CDRs are covalently joined to human FR and/or Fc/Fc' regions to produce a functional antibody. Thus, for example, PCT International Publication Number WO92/04381 teaches the production and use of humanised murine RSV antibodies in which at least a portion of the murine FR regions have been replaced by FR regions of human origin. Such antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for  $F(ab')_2$ , Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric  $F(ab')_2$  fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies. Thus, the invention can involve polypeptides of numerous sizes and types that bind specifically or selectively to polypeptides and proteins in accordance with the invention. These polypeptides may be derived also from sources other than antibody technology. For example, such polypeptide binding agents can be provided by degenerate peptide libraries which can be readily prepared in solution, in immobilised form or as phage display libraries. Combinatorial libraries can also be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent a completely degenerate or biased array. One can then select phage-bearing inserts which bind to a polypeptide or protein in accordance with the invention. This process can be repeated through several cycles of reselection of phage that bind to a polypeptide or protein in accordance with the invention. Repeated rounds lead to enrichment of phage bearing particular sequences. DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to a polypeptide or protein in accordance with the invention can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Thus, a polypeptide or protein in accordance with the invention can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding partners of the polypeptides of the invention. Such molecules can be used, as described, for screening assays, for diagnostic assays, for purification protocols or for targeting drugs, toxins and/or labelling agents (e.g. radioisotopes, fluorescent molecules, etc.) to cells which express a polypeptide or protein in accordance with the invention on the cell surface. Such binding agent molecules can also be prepared to bind complexes of a polypeptide or protein in accordance with the invention and an HLA molecule by selecting the binding agent using such complexes. Drug molecules that would disable or destroy tumour cells which express such complexes are known to those skilled in the art and are commercially available. For example, the immunotoxin art provides examples of toxins which are effective when delivered to a cell by an antibody or fragment thereof. Examples of toxins include ribosome-damaging toxins derived from plant or bacterial such as ricin, abrin, saporin, Pseudomonas endotoxin, diphtheria toxin, A chain toxins, blocked ricin, etc.

The invention as described herein has a number of uses, some of which are described herein. First the invention permits the diagnosis of a disorder

characterised by an expression of a polypeptide or protein in accordance with the invention. The methods can involve determining expression of the gene coding for a polypeptide or protein in accordance with the invention. In the former situation, such determinations can be carried out by any standard nucleic acid determination  
5 assay, including the polymerase chain reaction or assaying with labelled hybridisation probes, while in the latter situation, assaying with polypeptide-binding agents in accordance with the invention, such as antibodies, is preferred. An alternative method for determination is an assay for recognition of a TRA/HLA complex by a peptide-specific CTL by assaying for CTL activity. Such assays include  
10 a TNF release assay, of the type described below, a chromium release assay or a technique called ELISPOT in which CTL activity can be detected via antibody detection of IFN- $\gamma$  or TNF $\alpha$  release (Schmittl et al (1997). J. Immunol. Methods 210:167-174 and Lalvani et al. J. Exp. Med. 186:859-865 (1997)).

15 Other TRAPs or TRAs recognised by the CTL clones described herein may be isolated by the procedures detailed herein.

A variety of methodologies well known to the skilled practitioner can be utilised to obtain isolated TRA and TRAP molecules such as those which are the subject of the  
20 present invention. The protein may be purified from cells which naturally produce the protein. Alternatively, an expression vector may be introduced into cells to cause production of the protein. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause the production of the encoded protein. Translation of mRNA in cell-free extracts such as reticulocyte  
25 lysate system also may be used to produce protein. Peptides comprising TRAs of the invention may also be synthesised *in vitro*. Those skilled in the art can also readily follow known methods for isolating proteins in order to obtain isolated TRAPs and/or TRAs derived therefrom. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange  
30 chromatography and immune-affinity chromatography.

Polypeptides or proteins in accordance with the invention or complexes thereof with HLA, again in accordance with the invention, may be combined with materials



such as adjuvants to produce vaccines useful in treating disorders characterised by expression of a polypeptide or protein in accordance with the invention.

Certain therapeutic approaches based upon the disclosure are premised on a response by the subject's immune system, leading to lysis of TRA presenting cells. One such approach is the administration of autologous CTLs specific to the complex to a subject with abnormal cells of the phenotype at issue. It is within the skill of the artisan to develop such CTLs *in vitro*. Generally, a sample of cells taken from a subject, such as blood cells, are contacted with a cell presenting the complex and capable of provoking CTLs to proliferate. The target cell can be a transfectant, such as a COS cell. These transfectants present the desired complex on their surface and, when combined with a CTL of interest, stimulate its proliferation. COS cells, such as those used herein are widely available, as are other suitable host cells. Specific production of a CTL is well known to one of ordinary skill in the art. One method for selecting antigen-specific CTL clones has recently been described (Altman et al., Science 274:94-96, 1996; Dunbar et al., Curr. Biol. 8:413-416, 1998), in which fluorogenic tetramers of MHC class I molecule/peptide complexes are used to detect specific CTL clones. Briefly, soluble MHC class I molecules are folded *in vitro* in the presence of  $\beta_2$ -microglobulin and a peptide antigen which binds the class I molecule. After purification, the MHC/peptide complex is purified and labelled with biotin. Tetramers are formed by mixing the biotinylated peptide-MHC complex with labelled avidin (e.g. phycoerythrin) at a molar ratio of 4:1. Tetramers are then contacted with a source of CTLs such as peripheral blood or lymph node. The tetramers bind CTLs which recognise the peptide antigen/MHC class I complex. Cells bound by the tetramers can be sorted by fluorescence activated cell sorting to isolate the reactive CTLs. The isolated CTLs then can be expanded *in vitro*. The clonally expanded autologous CTLs then can be administered to the subject. Other CTLs specific to a polypeptide or protein in accordance with the invention may be isolated and administered by similar methods.

30

To detail a therapeutic methodology, referred to as adoptive transfer (Greenberg, J. Immunol. 136(5):1917, 1986; Riddell et al. Science 257:238, 1992; Lynch et al, Eur. J. Immunol. 21:1403-1410, 1991; Kast et al., Cell 59:603-614, 1989), cells presenting

the desired complex are combined with peripheral blood lymphocytes containing CTLs leading to proliferation of the CTLs specific thereto. The proliferated CTLs are then administered to a subject with a cellular abnormality which is characterised by certain of the abnormal cells presenting the particular complex. The CTLs then  
5 lyse the abnormal cells, thereby achieving the desired therapeutic goal.

The foregoing therapy assumes that at least some of the subject's abnormal cells present the relevant HLA/TRA complex. This can be determined very easily, as the art is very familiar with methods for identifying cells which present a particular  
10 HLA molecule, as well as how to identify cells expressing DNA or protein of the pertinent sequences. In this case, *MAGE-A10* expression could be determined, for example, by conducting a PCR assay using primers from unique parts of the *MAGE-A10* DNA. Alternatively, other well known antibody based techniques can be employed to identify cells presenting a relevant TRA/HLA complex. Once cells  
15 presenting the relevant complex are identified via the foregoing screening methodology, they can be combined with a sample from a patient containing CTLs. If the complex presenting cells are lysed by the mixed CTL sample, then it can be assumed that the TRA is being presented, and the subject is an appropriate candidate for the therapeutic approaches set forth herein.

20 Adoptive transfer is not the only form of therapy that is available in accordance with the invention. CTLs can also be provoked *in vivo*, using a number of approaches.

25 One approach is the use of non-proliferative cells expressing the complex as vaccines. Such vaccines can be prepared from cells, which can be host cells in accordance with the invention, that present TRA/HLA complexes on their surface. The cells used in this approach may be those that normally express the complex, such as irradiated non-proliferative tumour cells or non-proliferative transfectants  
30 etcetera. Chen et al., Proc. Natl. Acad. Sci. USA 88:110-114 (1991) exemplifies this approach, showing the use of transfected cells expressing HPV E7 peptides in a therapeutic regime. Various cell types may be used. Similarly, vectors carrying one or both of the genes of interest may be used. Viral or bacterial vectors are

especially preferred. For example, nucleic acids which encode a polypeptide or protein in accordance with the invention may be operably linked to promoter and enhancer sequences which direct expression of the polypeptide or protein in accordance with the invention in certain tissues or cell types. The nucleic acid may be incorporated into an expression vector. Expression vectors may be unmodified extrachromosomal nucleic acids, plasmids or viral genomes constructed or modified to enable insertion of exogenous nucleic acids, such as those encoding a polypeptide or protein in accordance with the invention. Nucleic acids encoding a polypeptide or protein in accordance with the invention also may be inserted into a retroviral genome, thereby facilitating integration of the nucleic acid into the genome of the target tissue or cell type. In these systems, the gene of interest is carried by a microorganism, e.g., a vaccinia virus, retrovirus or the bacteria BCG, and the materials *de facto* "infect" host cells. The cells which result present the complex of interest, and are recognised by autologous CTLs, which then proliferate. In all cases where cells are used as a vaccine, these can be cells transfected with coding sequences for one or both of the components necessary to provoke a CTL response, or be cells which already express both molecules without the need for transfection. These cells can also be antigen presenting cells (APCs), such as dendritic cells (DC) which have been "pulsed" with the TRAs of the invention or peptides derived therefrom (Nestle et al. Nat. Med. 4:328-332, 1998; Mukherji et al. Proc. Nat. Acad. Sci. USA. 92:8078-8082, 1995; Hu et al. Cancer Res. 56:2479-2483, 1996).

Vaccines also encompass naked DNA or RNA, encoding a polypeptide or protein in accordance with the invention, which may be produced *in vitro* and administered via injection, particle bombardment, nasal aspiration and other methods. Vaccines of the "naked nucleic acid" type have been demonstrated to provoke an immunological response including generation of CTLs specific for the peptide encoded by the naked nucleic acid (Science 259:1745-1748, 1993). When "disorder" is used herein, it refers to any pathological condition where the tumour rejection antigen precursor is expressed. An example of such a disorder is cancer, particularly melanoma.

A similar effect can be achieved by combining a polypeptide or protein in accordance with the invention with an adjuvant to facilitate incorporation into HLA presenting cells *in vivo*. The polypeptide or protein in accordance with the invention complexes with a molecule which presents the polypeptide or protein in accordance with the invention without the need for further processing. Generally, subjects can receive an intradermal injection of an effective amount of a polypeptide or protein in accordance with the invention. Initial doses can be followed by booster doses, following immunisation protocols standard in the art.

Especially preferred are nucleic acids encoding a series of epitopes, known as "polytopes". The epitopes can be arranged in sequential or overlapping fashion (see, e.g. Thompson et al, Proc. Natl. Acad. Sci. USA 92:5845-5849, 1995; Gilbert et al, Nature Biotechnol. 15:1280-1284, 1997) with or without the natural flanking sequences, and can be separated by unrelated linker sequences if desired. The polytope is processed to generated individual epitopes which are recognized by the immune system for generation of immune responses.

Thus, for example, peptides in accordance with the invention and which are presented by MHC molecules and recognised by CTL or T helper lymphocytes can be combined with peptides from other tumour rejection antigens (e.g. by preparation of hybrid nucleic acids or polypeptides) to form "polytopes". Exemplary tumour associated peptide antigens that can be administered to induce or enhance an immune response are derived from tumour associated genes and encoded proteins including MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-5, MAGE-6, MAGE-7, MAGE-8, MAGE-9, MAGE-10, MAGE-11, MAGE-12, MAGE 13, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7, GAGE-8, BAGE-1, RAGE-1, RAGE-2, RAGE-3, RAGE-4, LB33/MUM-1, DAGE (PRAME), NAG, MAGE-Xp2 (MAGE-B2), MAGE-Xp3, (MAGE-B3), MAGE-Xp4 (MAGE-B4), tyrosinase, brain glycogen phosphorylase, Melan-A, MAGE-C1, MAGE-C2, NY-ESO-1, LAGE-1, SSX-1, SSX-2 (HOM-MEL-40), SSX-4, SSX-5, SCP-1 and CT-7. for example, antigenic peptides characteristic of tumour include those listed in Table A below.

Table A: Exemplary Antigens

Gene	MHC	Peptide	Position	SEQ ID NO:
MAGE-1	HLA-A1	EADPTGHSY	161-169	8
	HLA-Cw16	SAYGEPRKL	230-238	9
MAGE-1	HLA-A1	EVDPIGHLV	168-176	10
	HLA-A2	FLWGPRLV	271-279	11
	HLA-B44	MEVDPIGHLV	168-176	12
BAGE	HLA-Cw16	AARAVFLAL	2-10	13
GAGE-1,2	HLA-Cw16	YRPRPRRY	9-16	14
RAGE	HLA-B7	SPSSNRIRNT	11-20	15
GnT-V	HLA-A2	VLPDVFIRC(V)	2-10/11	16,17
MUM-1	HLA-B44	EEKLIVVLF	exon 2/intron	18
		EEKLSVVLF (wild type)		19
CDK4	HLA-A2	ACDPHSGHFV	23-32	20
		ARDPHSGHFV (wild type)		21
$\beta$ -catenin	HLA-A24	SYLDSGIHF	29-37	22
		SYLDSGIHS (wild type)		23
Tyrosinase	HLA-A2	MLLAVLYCL	1-9	24
	HLA-A2	YMNGTMSQV	369-377	25
	HLA-A2	YMDGTMSQV	369-377	41
	HLA-A24	AFLPWHRLF	206-214	26
	HLA-B44	SEIWRDIDF	192-200	27
	HLA-B44	YEIWRDIDF	192-200	28
	HLA-DR4	QNILLSNAPLGPQFP	56-70	29
	HLA-DR4	DYSYLQDSDPDSFQD	448-462	30

MELAN- A <sup>MART-1</sup>	HLA-A2	(E)AAGIGILTV	26/27-35	31,32
	HLA-A2	ILTVILGVL	32-40	33
gp100 <sup>Pmel 117</sup>	HLA-A2	KTWGQYWQV	154-162	34
	HLA-A2	ITDQVPFSV	209-217	35
	HLA-A2	YLEPGPVTA	280-288	36
	HLA-A2	LLDGTATLRL	457-466	37
	HLA-A2	VLYRYGSFSV	476-485	38
DAGE (PRAME)	HLA-A24	LYVDSLFFL	301-309	39
MAGE-6	HLA-Cw16	KISGGPRISYPL	292-303	40

Other examples will be known to one of ordinary skill in the art (for example, see  
 5 Coulie, Stem Cells 13:393-403, 1995) and can be used in the invention in a like  
 manner as those disclosed herein. One of ordinary skill in the art can prepare  
 polypeptides comprising one or more *MAGE-A10* peptides and one or more of the  
 foregoing tumour rejection peptides, or nucleic acids encoding such polypeptides,  
 according to standard procedures of molecular biology.

10

Thus polytopes are groups of two or more potentially immunogenic or immune  
 response stimulating peptides which can be joined together in various arrangements  
 (e.g. concatenated, overlapping). The polytope (or nucleic acid encoding the  
 polytope) can be administered in a standard immunization protocol, e.g. to animals,  
 15 to test the effectiveness of the polytope in stimulating, enhancing and/or provoking  
 an immune response.

The polypeptides can be joined together to directly or via the use of flanking  
 sequences to form polytopes, and the use of polytopes as vaccines is well known in  
 20 the art (see e.g., Thomson et al. Proc. Acad. Sci USA 92(13):5485-5849), 1995;

Gilbert et al, Nature Biotechnol. 15(12):1280:1284, 1997; Thomson et al., J. Immunol. 157(2):822:826, 1996; Tam et al., J. Exp. Med. 171(1):299-306, 1990). For example, Tam showed that polytopes consisting of both MHC class I and class II binding epitopes successfully generated antibody and protective immunity in a mouse model. Tam also demonstrated that polytopes comprising "strings" of epitopes are processed to yield individual epitopes which are presented by MHC molecules and recognised by CTLs. Thus polytopes containing various numbers and combinations of epitopes can be prepared and tested for recognition by CTLs and for efficacy in increasing an immune response.

It is known that tumours express a set of tumour antigens, of which only certain subsets may be expressed in the tumour of any given patient. Polytopes can be prepared which correspond to the different combination of epitopes representing the subset of tumour rejection antigens expressed in a particular patient. Polytopes can be prepared to reflect a broader spectrum of tumour rejection antigens known to be expressed by a tumour type. Polytopes can be introduced to a patient in need of such treatment as polypeptide structures, or via the use of nucleic acid delivery systems known in the art (see. e.g., Allsop et al., Eur. J. Immunol. 26(8):1951-1959, 1996). Adenovirus, pox virus, Ty-virus like particles, adeno-associated virus, plasmids, bacteria, etc. can be used in such a delivery. One can test the polytope delivery systems in mouse models to determine efficacy of the delivery system. The systems can also be tested in human clinical trials.

As part of the immunisation protocols, substances which potentiate the immune response may be administered with the nucleic acid or peptide components of a pharmaceutical composition or a cancer vaccine in accordance with the invention. Such immune response potentiating compound may be classified as either adjuvants or cytokines. Adjuvants may enhance the immunological response by providing a reservoir of antigen (extracellularly or within macrophages), activating macrophages and stimulating specific sets of lymphocytes. Adjuvants of many kinds are well known in the art; specific examples include MPL (SmithKline Beecham), a congener obtained after purification and acid hydrolysis of *Salmonella minnesota* Re 595 lipopolysaccharide. QS21 (SmithKline Beecham), a pure QA-21 saponin purified

from *Quillja saponaria* extract, and various water-in-oil emulsions prepared from biodegradable oils such as squalene and/or tocopherol. Cytokines are also useful in vaccination protocols as a result of lymphocyte stimulatory properties. Many cytokines useful for such purposes will be known to one of ordinary skill in the art, including interleukin-12 (IL-12) which have been shown to enhance the protective effects of vaccines (Science 268:1432-1434, 1995), GM-CSF and IL-18. As envisaged herein, cytokines can be produced *in vivo* by cells transformed or transfected to express nucleic acid molecules coding therefor.

There are a number of additional immune response potentiating compounds that can be used in vaccination protocols. These include co-stimulatory molecules provided in either protein or nucleic acid form. Such co-stimulatory molecules include the B7-1 and B7-2 (CD80 and CD86 respectively) molecules which are expressed on dendritic cells (DC) and interact with the CD28 molecule expressed on the T cell. This interaction provides costimulation (signal 2) to an antigen/MHC/TCR stimulated (signal 1) T cell, increasing cell proliferation and effector function. B7 also interacts with CTLA4 (CD152) on T cells and studies involving CTLA4 and B7 ligands indicate that the B7-CTLA4 interaction can enhance antitumour immunity and CTL proliferation (Zheng et al., Proc. Nat'l Acad. Sci. USA 95:6284-6289, 1998).

B7 typically is not expressed on tumour cells so they are not efficient antigen presenting cells (APCs) for T cells. Induction of B7 expression would enable the tumour cells to stimulate more efficiently CTL proliferation and effector function. A combination of B7/IL-6/IL-12 costimulation has been shown to induce IFN-gamma and a Th1 cytokine profile in the T cell population leading to further enhanced T cell activity (Gajewski et al., J. Immunol. 154:5637-5648, 1995). Tumour cell transfection with B7 has been discussed in relation to *in vitro* CTL expansion for adoptive transfer immunotherapy by Wang et al., (J. Immunol. 150:1-8, 1993). Other delivery mechanisms for the B7 molecule would include nucleic acid (naked DNA) immunization (Kim et al., Nature Biotechnol. 15:7:641-646, 1997) and recombinant viruses such as adeno and pox (Wendtner et al., Gene Ther. 4:726-735, 1997). These systems are all amenable to the construction and use of expression



cassettes for the coexpression of B7 with other molecules of choice, such as polypeptides or proteins in accordance with the invention (including polytopes), or cytokines. These delivery systems can be used for induction of the appropriate molecules in vitro vaccination situations. The use of anti-CD28 antibodies to  
5 directly stimulate T cells in vitro and in vivo could also be considered.

Lymphocyte function associated antigen-3 (LFA-3) is expressed on APCs and some tumour cells and interacts with CD2 expressed on T cells. This interaction induces T cell IL-2 and IFN-gamma production and can thus complement but not  
10 substitute, the B7/CD28 co-stimulatory interaction (Parra et al., J. Immunol., 158:637-642, 1997; Fenton et al., J. Immunother. 21:95-108, 1998).

Lymphocyte function associated antigen-1 (LFA-1) is expressed on leukocytes and interacts with ICAM-1 expressed on APCs and some tumour cells. This interaction  
15 induces T cell IL-2 and IFN-gamma production and can thus complement but not substitute, the B7/CD28 co-stimulatory interaction (Fenton et al., 1998). LFA-1 is thus a further example of a co-stimulatory molecule that could be provided in a vaccination protocol in the various ways discussed above for B7.

Complete CTL activation and effector function requires Th cell help through the interaction between the Th cell CD40L (CD40 ligand) molecule and the CD40 molecule expressed by DCs (Ridge et al., Nature 393:474, 1998; Bennett et al., Nature 393:478, 1998; Schoenberger et al., Nature 393:480, 1998). This mechanism of this co-stimulatory signal is likely to involve upregulation of B7 and associated  
20 IL-6/IL-12 production by the DC (APC). The CD40-CD40L interaction thus complements the signal 1 (antigen/MHC-TCR) and signal 2 (B7-CD28) interactions.

The use of anti-CD40 antibodies to stimulate DC cells directly, would be expected to enhance a response to tumour associated antigens which are normally  
30 encountered outside of an inflammatory context or are presented by non-professional APCs (tumour cells). In these situations Th help and B7 costimulation signals are not provided. This mechanism might be used in the context of antigen

pulsed DC based therapies or in situations where Th epitopes have not been defined within known tumour associated antigen precursors.

Pharmaceutical compositions in accordance with the present invention can be formulated with conventional pharmaceutically acceptable carriers and excipients, either for systemic or local administration. Such carriers and excipients can be selected without difficulty by those skilled in the art and include those which provide for immediate and sustained release.

10 The present invention involves the generation of *MAGE*-specific CTLs from a patient other than MZ2 by MLTC for the first time. A CTL clone (CTL 477A/5) was generated that recognises the nonapeptide (TRA) GLYDGMEHL (SEQ. ID. NO. 42) encoded by *MAGE-A10* in the context of HLA-A2. Its overlapping decapeptide (TRA) GLYDGMEHLI (SEQ. ID. NO. 44) could also sensitise target  
15 cells to be lysed by the CTL, but less efficiently. CTL 447A/5 recognised not only autologous tumour cells but *MAGE-A10*+ tumour cells from other HLA-A2 patients (Fig. 6), suggesting that GLYDGMEHL (SEQ. ID. NO. 42) is a common TRA presented in tumours expressing *MAGE-A10* and HLA-A2. *MAGE-A10* is expressed in tumours more frequently than previously anticipated. By reverse-  
20 transcription-PCR, the expression of *MAGE-A10* gene has been detected in a variety of tumours, including melanomas, lung cancers, head and neck carcinomas, bladder carcinomas, myelomas, prostatic carcinomas, and (see table 2 below). As observed for other *MAGE* genes, the only normal tissue expressing *MAGE-A10* is testis.

25 Clinical trials have also been under way to treat melanoma patients with peptides derived from *MAGE-A1* and *MAGE-A3*. A few patients showed objective tumour regressions after being immunised with pure peptides, though peptide-specific CTL responses were not detected (Marchand, M., et al., 1995, *Int. J. Cancer*. 63:883- 885).  
30 When immunised with peptide-pulsed antigen presenting cells or dendritic cells, quite a few patients developed peptide-specific delayed-type hypersensitivity or CTL responses (Nestle, F.O., et al., 1998, *Nat. Med.* 4:328-332; Mukherji, B., et al., 1995, *Proc. Natl. Acad. Sci. USA*. 92:8078-8082; and Hu, X., et al., 1996, *Cancer Res.*

56:2479-2483). One of the obstacles in cancer immunotherapy is the occurrence of antigen loss tumour variants. Since most tumours expressing *MAGE-A10* also express *MAGE-A1* or/and *MAGE-A3* (F. Brasseur, unpublished data), it is anticipated that addition of peptides in accordance with the present invention in a cocktail vaccination will improve the anti-tumour effect by targeting several different antigens.

The following examples show the generation of cytolytic T lymphocytes (CTLs) from patent LB 1751, using MLTC techniques, that lysed specifically autologous tumour cells and produced tumour necrosis factor (TNF) upon stimulation with target cells expressing *MAGE-A10*. The recognition by the CTLs was shown to be restricted by HLA-A2.1 and the antigen was found to be encoded by *MAGE-A10* in the region of nt 547-825. From the amino acid sequence corresponding to this region, four peptides were found that had the potential to bind to HLA-A2.1. The expression of *MAGE-A10* has been detected in a variety of tumours, but not in normal tissues except testis and the identified antigenic peptides, therefore, clearly add to the repertoire of antigens that have the potential to be used in anti-tumoural vaccination trials.

#### **Brief description of the Sequences**

SEQ. ID. NO. 1 is the amino acid sequence of the protein encoded by the *MAGE-A10* gene;

SEQ. ID. NO. 2 is the amino acid sequence of the protein encoded for by the *MAGE-A8* gene;

SEQ. ID. NO. 3 is the nucleotide sequence of the *MAGE-A10* gene;

SEQ. ID. NO. 4 is the nucleic acid sequence of *MAGE-A10* cDNA, the region coding for the amino acid sequence in SEQ. ID. NO. 1 lies between bases 357 and 1466;

SEQ. ID. NO. 5 is the nucleotide sequence of the *MAGE-A8* gene;

SEQ. ID. No. 6 is a partial sequence of the *MAGE-A8* gene as published in WO92/20356, with the codons in the coding portion of the gene identified; and

SEQ. ID. NO. 7 is a partial sequence of the *MAGE-A10* gene as published in WO92/20356, with the codons in the coding portion of the sequence identified;

SEQ. ID. NOs. 8-41 are described in Table A;

SEQ. ID. NO. 42 is the nonapeptide with the amino acid sequence GLYDGMEHL;

SEQ. ID. NO. 43 is the nonapeptide with the amino acid sequence GLYDGREHS;

SEQ. ID. NO. 44 is the decapeptide with the amino acid sequence GLYDGMEHLI;

5 SEQ. ID. NO. 45 is the decapeptide with the amino acid sequence  
GLYDGREHSV;

SEQ. ID. NO. 46 is the nonapeptide with the amino acid sequence MLLVFGIDV;

SEQ. ID. NO. 47 is the decapeptide with the amino acid sequence CMLLVFGIDV;

SEQ. ID. NO. 48 is the nonapeptide with the amino acid sequence FLLFKYQMK;

10 SEQ. ID. NO. 49 is the nonapeptide with the amino acid sequence FIEGYCTPE;

SEQ. ID. NO. 50 is the nonapeptide with the amino acid sequence GLELAQAPL;

SEQ. ID. NO. 51 is the sense primer referred to in Example 3;

SEQ. ID. NO. 52 is the first anti-sense primer referred to in Example 3;

SEQ. ID. NO. 53 is the second anti-sense primer referred to in Example 3;

15 SEQ. ID. NO. 54 is the third anti-sense primer referred to in Example 3;

SEQ. ID. NO. 55 is the sense primer referred to in Example 6; and

SEQ. ID. NO. 56 is the anti-sense primer referred to in Example 6.

### Brief description of the Figures

20 **Figure 1.** Shows the specific lysis of autologous LB 1751-MEL cells by CTL 447A/5. Control targets included autologous EBV-transformed lymphoblastoid line LB1751-EBV and NK-sensitive line K562. Chromium release was measured after 4 h of incubation of chromium labelled target cells with the CTL at different effector to target ratios.

25 **Figure 2.** Shows the HLA-restricted recognition of LB1751-MEL cells by CTL 447A/5. LB1751-MEL cells alone or in the presence of mAbs with the specificities indicated were used to stimulate CTL 447A/5. After 24 h of coculture, production of TNF by the CTL was measured by testing toxicity of the supernatants to TNF-sensitive WEHI-164.13 cells.

30 **Figure 3.** Shows the identification of the region coding for the antigenic peptide recognised by CTL 447A/5. PCR fragments of different lengths as indicated were cloned into pcDNAI/Amp and cotransfected into COS-7 cells with gene HLA-

A2.1. Transfected cells were incubated for 24 h with CTL 447A/5 and the TNF in the supernatants was measured by its toxicity to WEHI-164.13 cells.

**Figure 4.** Shows the extent of lysis by CTL 447A/5 of peptide-sensitised LB1751-EBV cells. (A) LB1751-EBV cells pulsed with peptides derived from *MAGE-A10*. Chromium-labelled autologous EBV-transformed lymphoblastoid cells LB1751-EBV were pulsed for 30 min with peptides as indicated at various concentrations before addition of CTL 447A/5 at an E/T ratio of 20. Chromium release was measured after 4 h. (B) Enhancement by mAb MA2.1 of lysis of LB 1751-EBV cells pulsed with *MAGE-A10* peptides. LB1751-EBV cells were pre-treated with or without anti-HLA-A2 antibody MA2.1. The pre-treatment was performed by adding mAb MA2.1 during  $^{51}\text{Cr}$ -labeling. Peptide sensitisation and chromium release assay were carried out as in (A).

**Figure 5.** Shows the extent of lysis by CTL 447A/5 of LB1751-EBV cells sensitised with peptides derived from *MAGE-A8*. LB1751-EBV cells were pre-treated with or without anti-HLA-A2 antibody MA2. 1. Ab treatment and peptide sensitisation of the cells and chromium release assay were carried out as in Fig. 4.

**Figure 6.** Shows the degree of recognition of allogenic tumour cell lines by CTL 447A/5. LB373-MEL (*MAGE-A10+*), AVL3-MEL (*MAGE-A10+*) and TT (*MAGE-A8+*) cell lines derived from HLA-A2 patients were used to stimulate CTL 447A/5. Autologous tumour cell line LB1751-MEL was included as a control. After 24 h of coculture, production of TNF by the CTL was measured by testing toxicity of the supernatants to TNF-sensitive WEHI-164.13 cells.

**Figure 7.** Shows the amino acid sequence of the protein encoded by the *MAGE-A10* gene (SEQ. ID. NO. 1).

**Figure 8.** Shows the amino acid sequence of the protein encoded for by the *MAGE-A8* gene (SEQ. ID. NO. 2).

**Figure 9.** Shows the nucleotide sequence of the *MAGE-A10* gene (SEQ. ID. NO. 3).

**Figures 10a and 10b.** Show the nucleic acid sequence of *MAGE-A10* cDNA, the region coding for the amino acid sequence in SEQ. ID. NO. 1 lying between bases 357 and 1466 (SEQ. ID. NO. 4).

**Figures 11a and 11b.** Show the nucleotide sequence of the *MAGE-A8* gene (SEQ. ID. NO. 5).

Figure 12. Shows a partial sequence of the *MAGE-A8* gene as published in WO92/20356, with the codons in the coding portion of the gene identified (SEQ. ID. No. 6).

Figure 13. Shows a partial sequence of the *MAGE-A10* gene as published in WO92/20356, with the codons in the coding portion of the sequence identified (SEQ. ID. NO. 7).

### Example 1

*Preparation of CTL Clones against LBI 751 -MEL and identification HLA-A2.1 as on the presenting MHC molecule.*

Melanoma cell line LB1751-MEL was derived from a metastatic melanoma in axillary lymph nodes of a 67-yr-old male patient LB1751 and grown by a method previously described (Van den Eynde, B., et al., 1989, *Int. J. Cancer*. 44:634-640).

At passage 4 after the initiation of LB1751-MEL culture, aggregates of typical EBV-transformed lymphoblastoid cells appeared in the supernatant. They were collected and cultured separately to obtain B cell line LB 1751-EBV. Melanoma culture LB1751-MEL was cleared of EBV-transformed B cells by limiting dilution cloning. DNA fingerprint confirmed that LB 1751-MEL and LB 1751-EBV originated from the same patient (data not shown). A panel of CTL clones was generated by MLTC as described previously with minor modifications (Herin, M., et al., 1987, *Int. J. Cancer*. 39:390-396). Briefly, MLTC was carried out by culturing PBL of patient LB1751 with irradiated LB1751-MEL cells in an 8% CO<sub>2</sub> incubator in Iscove's modified Dulbecco's medium (GIBCO BRL, Gaithersburg, MD) supplemented with 10 mM Hepes buffer, L-arginine (116µg/ml), L-asparagine (36µg/ml), L-glutamine (216g/ml), 10% human serum, and 5 ng/ml of recombinant human IL-7 (rhIL-7) (Genzyme, Cambridge, MA). On day 3, rhIL-2 (Eurocetus, Amsterdam, Netherlands) was added at a final concentration of 25 U/ml. Lymphocytes were restimulated weekly with irradiated LB1751-MEL cells in fresh medium containing 25U/ml of rhIL-2 and 5 ngl/ml of rhIL-7. On day 21, CD8+ T lymphocytes were sorted by using anti-CD8-conjugated MACS magnetic MicroBeads (MACS, Miltenyi Biotec GmbH, Germany) and cloned by limiting dilution. The resulting panel of CTL clones specifically lysed LB1751-MEL cells, but not autologous EBV-

transformed B cell line LB 1751-EBV or NK-sensitive cell line K562. Lysis of target cells was tested by chromium release as previously described in (Boon, T., et al., 1980, *J. Exp. Med.* 152:1184-1193) and the results of these tests for representative CTL clone 447A/5 are shown in Fig. 1.

5

The ability of CTL clone 447A/5 to produce TNF when stimulated with LB1751-MEL cells was confirmed using the technique described in (Traversari, C., et al., 1992, *Immunogenetics*. 35:145-152). Briefly,  $2 \times 10^4$  tumour cells were grown for 24 h. The medium was discarded and 3,000 CTL were added to the microwells in 100  $\mu$ l of Iscove's modified Dulbecco's medium supplemented with 10% human serum and 25 U/ml rhIL-2. After 24 h, the supernatant was collected and its TNF content was determined by testing its cytotoxic effect on WEHI 164 clone 13 cells (Espevik, T., et al., 1986, *J. Immunol. Methods*. 95:99-105) in a MTT colorimetric assay (Traversari, C., et al., 1992, *Immunogenetics*. 35:145-152; and Hansen, M. B., et al., 1989, *J. Immunol. Methods*. 119:203-210). Inhibition of TNF production by mAbs W6/32 (anti-HLA class I) (Barnstable, C.J., et al., 1978, *Cell*. 14:9-20), BB7.2 (anti-HLA-A2) (Parham, P., and F.M. Brodsky, 1981, *Hum. Immunol.* 3:277-299), and B1.23.2 (anti-HLA-B and -C) (Rebai, N., and B. Malissen, 1983, *Tissue Antigens*. 22:107-117) was tested by adding a 1/20 dilution of ascites to the test, and it was found that production of TNF was inhibited by mAbs W6/32 (anti-HLA class I) and BB7.2 (anti-HLA-A2), but not by mAb B1.23.2 (anti-HLA-B, -C) (Fig. 2), indicating that the target antigen is presented by HLA-A2. The results of the test are set out in Figure 2.

## 25 Example 2

### *Identification of the genes encoding the antigen recognised by CTL 447A/5*

Because of the high level expression of almost all the *MAGE-A* genes in melanoma cell line LB1751-MEL (data not shown), the possibility that CTL 447A/5 recognises an antigen encoded by one of the *MAGE-A* genes was tested. COS-7 cells were cotransfected with the cDNA of *MAGE-A* genes cloned in expression vector pcDNA1/Amp together with pcDNA1/Amp-A2, a construct encoding the HLA-A2.1. Transfection was performed by the DEAE-dextran-chloroquine method

30

(Seed, B., et al., 1987, *Proc. Natl. Acad. Sci. USA*. 84:3365-3369). Briefly,  $2 \times 10^4$  COS-7 cells were transfected with 100 ng of plasmid pcDNAI/Amp-A2, a recombinant plasmid containing the HLA-A2.1 gene isolated from a CTL clone of patient SK29 (Wolfel, T., et al., 1993, *Int. J. Cancer*. 55:237-244), and 100 ng of DNA of *MAGE-A* genes cloned in pcDNAI/Amp. The transfectants were grown for 48 hours and then tested for their ability to stimulate TNF production by CTL 447A/5 by the method described in Example 1. The tests revealed that a very significant amount of TNF was produced by CTL 447A/5 when stimulated with COS-7 cells transfected with *MAGE-A10* DNA. Transfectants with *MAGE-A8* cDNA could also stimulate CTL 447A/5 to produce TNF, but less efficiently than those with *MAGE-A10* cDNA. No stimulation was observed with COS-7 cells transfected with HLA-A2.1 alone or with the combination of HLA-A2.1 and any of the other *MAGE-A* genes. The results of these tests are set out in table 1.

Table 1. Stimulation of CTL 447A/5 by COS-7 cells transfected with HLA-A2.1 and *MAGE-A* genes

Stimulator cells	TNF released by CTL 447A/5 (pg/ml)
LB1751-MEL	28
COS	7
COS+HLA-A2.1	4
COS+HLA-A2.1 +	
MAGE-A1	3
MAGE-A2	4
MAGE-A3	4
MAGE-A4	4
MAGE-A6	4
MAGE-A8	30
MAGE-A9	3
MAGE-A10	>120
MAGE-A11	4
MAGE-A12	2

Control stimulator cells included autologous LB1751-MEL, untransfected COS-7 cells, and COS-7 cells transfected only with HLA-A2.1 gene.



### Example 3

#### *Identification of the MAGE-A10 Antigenic Peptides.*

Fragments of different lengths starting from the initiation codon of *MAGE-10* (nucleotide 1955 in SEQ. ID. NO. 3) were generated by PCR amplification. The 1.1-kb open reading frame (ORF) of *MAGE-A10* was cloned in plasmid vector pcDNA1/Amp (Invitrogen Corporation, Oxon, UK). Three fragments containing the first 270, 546 and 825 nucleotides of the *MAGE-A10* open reading frame (ORF) (nucleotides 1955-3064 in SEQ. ID. No. 3) were amplified by PCR using sense primer 5'-GGAATTCATCATGCCTCGAGCTCCAAAGC-3' (SEQ. ID. NO. 51) and three anti-sense primers 5'-GCTCTAGAGCTTAGGCTATCTGAGCACTCTG-3' (SEQ. ID. NO. 52), 5'-GCTCTAGAGCTTAGCACTCGGAGGCTTCACT-3' (SEQ. ID. NO. 53), and 5'-GCTCTAGAGCTTACCAATCTTGGGTGAGCAG-3' (SEQ. ID. NO. 54) respectively. For PCR amplification *Pfu* DNA polymerase (STRATAGENE, La Jolla, CA) was used. A first denaturation step was done for 5 min at 94°C. The first cycle of amplification was performed for 1 min at 94°C followed by 1 min at 53°C and 1 min at 72°C, and then additional 25 cycles were performed as follows: 1 min at 94°C, 1 min at 65°C, and 1 min at 72°C. Cycling was concluded with a final extension step of 15 min at 72°C.

The PCR products were digested with EcoRI and Xba I, unidirectionally cloned into the EcoRI and Xba 1 sites of plasmid pcDNA1/Amp and transfected into COS-7 cells together with pcDNA1/Amp-A2, using the DEAE-dextran-chloroquine method described in Example 2. A CTL stimulation assay was carried out with the transfectants in the manner described in Examples 1 and 2. As shown in Fig. 3, the fragment of 825 bp rendered the transfectants capable of stimulating TNF production by CTL 447A/5, and the 546 bp fragment did not, indicating that the sequence coding for the antigenic peptide is located between nt 547 and 825 of the *MAGE-A10* ORF.

In the amino acid sequence corresponding to the nucleotides 547-825 there are two nonapeptides, MLLVFGIDV (codons 183-191 in the ORF) (SEQ. ID. NO. 46) and GLYDGMEHL (254-262) (SEQ. ID. NO. 42), which conform to the HLA-A2.1

peptide binding motif, i.e., a nona- or decapeptide with Leu or Met at position 2 and Leu, Val or Ile at its C-terminus (Rammensee, H.G., et al., 1995, *Immunogenetics*. 41:178-228). These two peptides and their overlapping decapeptides were synthesised on solid phase using F-moc for transient NH<sub>2</sub>-terminal protection and characterised by mass spectrometry. The peptides were >90% pure, as indicated by analytical HPLC, and used to sensitise autologous lymphoblastoid cell line LB1751-EBV in a chromium release assay as described in (Boon, T., et al., 1980, *J. Exp. Med.* 152:1184-1193) but modified as follows. The target cells were <sup>51</sup>Cr-labeled for 1 h at 37°C and then washed extensively. 1,000 target cells were then incubated in 96-well microplates in the presence of various concentrations of peptides for 30 min at 37°C and CTLs were added at an E/T ratio of 20. Chromium release was measured after 4 h at 37°C.

It was found that the nonapeptide GLYDGMEHL (254-262) (SEQ. ID. NO. 42) and, less efficiently, the decapeptide GLYDGMEHLI (254-263) (SEQ. ID. NO. 44), could sensitise LB1751-EBV cells to lysis by CTL 447A/5 (Fig. 4A). When pre-treated with anti-HLA-A2 antibody MA2.1 for 1 h before peptide sensitisation, LB1751-EBV cells pulsed with both peptides showed a significantly increased sensitivity to lysis by the CTL (Fig. 4B). mAb MA2.1 can facilitate the binding of peptides to HLA-A2 molecules on the cell surface, thereby augmenting lysis of peptide-sensitised target cells by HLA-A2-restricted peptide-specific CTL (Bodmer, H., et al., 1989, *Nature* 342:443-446). Enhancement of peptide binding to the HLA-A2 molecule was achieved by incubation of target cells during <sup>51</sup>Cr-labeling with a 1/5 dilution of hybridoma culture supernatant of mAb MA2.1 (McMichael, A.J., et al., 1980, *Hum. Immunol.* 1:121-129; and Bodmer, H., et al., 1989, *Nature* 342:443-446). The other two peptides MLLVFGIDV (183-191) (SEQ. ID. NO. 46) and CMLLVFGIDV (182-191) (SEQ. ID. NO. 47) failed to confer recognition by the CTLs, even after LB1751-EBV cells were treated with mAb MA2. 1.

#### Example 4

##### *Identification of MAGE-A8 antigen peptides*

The sequence of *MAGE-A8*, which is homologous to that of the *MAGE-A10* gene

encoding GLYDGMEHL (SEQ. ID. NO. 42), codes for peptide GLYDGREHS (codons 232-240 in the *MAGE-A8* ORF) (SEQ. ID. NO. 43) that displays two amino acid changes at positions 6 and 9. This peptide and its overlapping decapeptide GLYDGREHSV (codons 232-241) (SEQ. ID. NO. 45) were synthesised by the technique described above. LB1751-EVB cells incubated with either of the peptides, at a concentration of as high as 10  $\mu$ M peptide, were not lysed by CTL 447A/5. However, when the peptide concentration was increased to 100  $\mu$ M could GLYDGREHS (SEQ. ID. NO. 43) did sensitise LB1751-EBV cells to lysis (Fig. 5). An enhancement of lysis was observed when the LB1751-EBV cells were pre-treated with mAb MA2.1 and pulsed with GLYDGREHS (SEQ. ID. NO. 43), but not GLYDGREHSV (SEQ. ID. NO. 45). Enhancement of peptide binding to the HLA-A2 molecule was achieved by incubation of target cells during  $^{51}$ Cr-labeling with a 1/5 dilution of hybridoma culture supernatant of mAb MA2.1 (McMichael, A.J., et al., 1980, *Hum. Immunol.* 1: 121-129; and Bodmer, H., et al., 1989, *Nature* 342:443-446).

### Example 5

#### *MAGE-A10+ Allo-tumours Present the Antigen Recognised by CTL 447A15.*

Using allogenic HLA-A2+ tumour cell lines that express *MAGE-A10* or *MAGEA8* as stimulator cells, a CTL stimulation assay of the type described above was performed to assess the TNF production by CTL 447A/5. Melanoma cell lines LB373-MEL and AVL3-MEL were derived from patients LB373 and AVL, respectively, and cultured in Iscove's modified Dulbecco's medium containing 10% FCS. Medullary thyroid carcinoma cell line TT (ATCC<sup>®</sup> No.: CRL1803) was obtained from the American Type Culture Collection (Rockville, MD) and maintained in DMEM supplemented with 10% FCS. The results of these assays are set out in Fig. 6 and show that two *MAGE-A10*+ cell lines LB373-MEL and AVL3-MEL could stimulate CTL 447A/5 to produce TNF, but *MAGE-A8*+ cell line TT could not. Moreover, AVL3-MEL cells were recognised by CTL 447A/5 less efficiently than LB373-MEL cells, which is consistent with the finding that the transcription level of *MAGE-A10* in AVL3-MEL was lower than that in LB373-MEL (Serrano, et, al. manuscript in preparation).

### Example 6

#### *MAGE-A10 is Expressed in a Variety of Tumours.*

5 As the expression of *MAGE-A10* has been studied only in a small number of tumours, a series of 314 tumours of various histological types were tested by RT-PCR with primers ensuring specificity for gene *MAGE-A10*. Briefly, reverse-transcription-PCR (RT-PCR) was performed to detect the expression of *MAGE-A10* in tumour tissues. Total RNA purification and cDNA synthesis were carried  
10 out as previously described (Weynants et al. Int. J. Cancer. 56:826-829, 1994). 1/40th of the cDNA produced from 2µg of total RNA was amplified using sense primer 5'-CACAGAGCAGCACTGAAGGAG-3' (SEQ. ID. NO. 55) and anti-sense primer 5'-CTGGGTAAAGACTCACTGTCTGG-3' (SEQ. ID. NO. 56), which yielded a 485-bp specific fragment of *MAGE-A10*. For PCR, a first denaturation  
15 step was done for 4 min at 94° and then 30 cycles of amplification were performed as follows: 1 min at 94°C, 1 min at 65°C, and 1 min at 72°C. Cycling was concluded with a final extension step of 15 min at 72°C. As shown in Table 2, *MAGE-A10* was expressed in a number of tumours of various histological types. The expression of some other *MAGE* genes was also examined by RT-PCR. Of the 71 tumour  
20 samples expressing *MAGE-A10*, all but two expressed simultaneously at least one of genes *MAGE-A1*, *A2*, *A3*, *A4* and *A6* (data not shown).

**Table 2. Expression of *MAGE-A10* in Tumors**

Tumor type	Positive samples/ samples tested *
Bladder carcinomas	
Superficial	5/15 (33%)
Infiltrating	5/15 (33%)
Brain tumors	0/9
Breast carcinomas	0/20
Colorectal carcinomas	0/20
Esophageal squamous carcinomas	6/15 (40%)
Head and neck squamous carcinomas	7/20 (35%)
Leukemias	0/25
Lung carcinomas	
Adenocarcinomas	6/15 (40%)
Squamous carcinomas	10/20 (50%)
Melanomas (of cutaneous origin)	
Primary lesions	4/19 (21%)
Metastases	21/45 (47%)
Mesotheliomas	0/4
Myelomas	3/15 (20%)
Neuroblastomas	2/2
Prostatic carcinomas	1/10 (10%)
Renal carcinomas	0/20
Sarcomas	1/15 (7%)
Thyroid carcinomas	0/5
Uterine carcinomas	0/5

\* Expression of *MAGE-A10* was tested by RT-PCR on total RNA with specific primers which give a 485-bp product when cDNA is amplified. Percentage of positive samples is shown in parentheses.

## Claims

1. An isolated polypeptide comprising an unbroken sequence of amino acids from SEQ ID. NO. 1, or 2, characterised by an ability to complex with a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1.
2. An isolated polypeptide comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1, or 2, characterised by an ability to elicit an immune response from human lymphocytes.
3. A nonapeptide comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1, or 2, wherein the amino acid adjacent to the N-terminal amino acid is L or M, preferably L, and the C-terminal amino acid is L, V, or I, preferably L.
4. A nonapeptide as claimed in claim 3, wherein the amino acid in position 3 is Y and/or the amino acid in position 4 is D and/or the amino acid in position 5 is G and/or the amino acid in position 7 is E and/or the amino acid in position 8 is H.
5. A polypeptide as claimed in any one of claims 1-4, other than a nonapeptide having any one of amino acid sequences:-
  - (a) FLLFKYQMK;
  - (b) FIEGYCTPE; or
  - (c) GLEGAQAPL.
6. A polypeptide as claimed in any one of claims 2-5, further characterised by an ability to complex with a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1.
7. A decapeptide comprising a nonapeptide as claimed in any of claims 3-5 and, preferably, an unbroken sequence of amino acids from SEQ. ID. NO. 1, or 2.
8. A nonapeptide having the amino acid sequence GLYDGMEHL or GLYDGREHS, preferably GLYDGMEHL.

9. A decapeptide having the amino acid sequence GLYDGMEHLI or GLYDGREHSV, preferably GLYDGMEHLI.
- 5 10. An isolated polypeptide of up to about 93 amino acids in length, characterised by comprising a nonapeptide or a decapeptide as claimed in any of claims 3-9.
11. A polypeptide as claimed in claim 10 comprising of an unbroken sequence of  
10 amino acids from SEQ. ID. NO. 1, or 2.
12. A polypeptide as claimed in any of the preceding claims, wherein the unbroken sequence is from SEQ. ID. NO. 1.
- 15 13. A polypeptide as claimed in any of the preceding claims and capable of eliciting an immune response from human lymphocytes.
14. A polypeptide as claimed in claim 13 and capable of eliciting an immune response from human lymphocytes when complexed with a major histocompatibility  
20 complex molecule type HLA-A2, preferably HLA-A2.1.
15. A polypeptide as claimed in claim 13 or claim 14, wherein said immune response is an cytolytic response from human T-lymphocytes.
- 25 16. An isolated polypeptide or protein comprising a polypeptide as claimed in any of claims 1-15, wherein the amino acid sequence of said isolated polypeptide or protein is not that set out in either of SEQ. ID. NOs. 1 and 2 or that coded for by nucleotides 334-918 of SEQ. ID. NO. 7.
- 30 17. An isolated polypeptide or protein which is a functionally equivalent homologue to a polypeptide or protein as claimed in any of claims 1-16, wherein the amino acid sequence of said isolated polypeptide or protein is not that set out in

either of SEQ. ID. NOs. 1 and 2 or that coded for by nucleotides 334-918 of SEQ. ID. NO. 7.

18. An isolated nucleic acid molecule comprising a nucleotide sequence coding  
5 for a polypeptide or protein as claimed in any of claims 1-16, or a complimentary  
nucleotide sequence, wherein said nucleotide sequence is not that set out in any of  
SEQ. ID. NOs. 3, 4, 5, 6 or 7.
19. A nucleic acid molecule as claimed in claim 18 and comprising an unbroken  
10 sequence of nucleotides from SEQ. ID. NO. 3, 4 or 5, or a complimentary  
sequence, or an RNA transcript of said nucleic acid molecule.
20. A nucleic acid molecule as claimed in claim 18 or claim 19, wherein said  
nucleotide sequence encodes a plurality of epitopes or a polytope.
- 15 21. An expression vector comprising a nucleic acid molecule as claimed in any of  
claims 18-20 operably linked to a promoter.
22. An expression vector as claimed in claim 21, further comprising a nucleotide  
20 sequence coding for a major histocompatibility complex molecule type HLA-A2,  
preferably HLA-A2.1, a cytokine or a co-stimulatory molecule, or a bacterial or viral  
genome or a portion thereof.
23. A host cell transformed or transfected with an expression vector as claimed  
25 in claim 21 or claim 22.
24. A host cell as claimed in claim 23, transformed or transfected with an  
expression vector coding for a major histocompatibility complex molecule type  
HLA-A2, preferably HLA-A2.1, a cytokine or a co-stimulatory molecule.
- 30 25. A polypeptide-binding agent which selectively binds or is specific for an  
isolated polypeptide or protein as claimed in any of claims 1-17.



26. A polypeptide-binding agent as claimed in claim 25, comprising an antibody, preferably a monoclonal antibody or an antibody fragment specific for an isolated polypeptide as claimed in any of claims 1-17.

5 27. A polypeptide-binding agent as claimed in claim 25 or claim 26 which selectively binds or is specific for a complex of a polypeptide as claimed in any of claims 1-17 and a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1, but which does not bind said major histocompatibility molecule alone.

10

28. A polypeptide-binding agent as claimed in any of claims 25-27, comprising a cytolytic T-cell which is specific for a complex of a polypeptide as claimed in any of claims 1-17 and a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1.

15

29. A polypeptide or protein as claimed in any of claims 1-17, an isolated nucleic acid molecule as claimed in any of claims 18-20, an expression vector as claimed in either of claims 21 or 22, a host cell as claimed in either of claims 23 or 24, or a polypeptide binding agent as claimed in any of claims 25-28, for use in the therapy, 20 prophylaxis or diagnosis of tumours.

25

30. A pharmaceutical composition for the prophylaxis, therapy or diagnosis of tumours comprising a polypeptide or protein as claimed in any of claims 1-17, a nucleic acid molecule as claimed in any of claims 18-20, an expression vector as claimed in either of claims 21 or 22, a host cell as claimed in either of claims 23 or 24, or a polypeptide binding agent as claimed in any of claims 25-28, optionally in admixture with a pharmaceutically acceptable carrier and optionally further comprising a major histocompatibility molecule type HLA-A2, preferably HLA-A2.1.

30

31. A pharmaceutical composition for the prophylaxis, therapy or diagnosis of tumours comprising a polypeptide or protein as claimed in any of claims 1-17 complexed with a major histocompatibility molecule, HLA, and presented on the

surface of an APC, preferably a dendritic cell, wherein said complex is formed by pulsing said APC with polypeptide or protein.

32. A cell, preferably an APC, and more preferably, a dendritic cell, which has  
5 been pulsed with a polypeptide or protein as claimed in any of claims 1-17 to present on its surface said polypeptide or protein as a complex with a major histocompatibility molecule, HLA.
33. A pharmaceutical composition as claimed in any of claims 30 and 31 further  
10 comprising a co-stimulatory molecule.
34. A method of diagnosing disease, preferably cancer, comprising contacting a biological sample isolated from a subject with an agent that is specific for a polypeptide or protein as claimed in any of claims 1-17, or a nucleic acid molecule  
15 as claimed in any of claims 18-20, and assaying for interaction between the agent and any of the polypeptide, protein or nucleic acid molecule either free in or forming an integral part of the sample as a determination of the disease.
35. A method as claimed in claim 34, wherein the agent is a polypeptide-binding  
20 agent as claimed in any of claims 25-28.
36. A method of producing a cytolytic T-cell culture reactive against tumour cells, comprising removing a lymphocyte sample from an individual and culturing the lymphocyte sample with a polypeptide or protein as claimed in any of claims 1-  
25 14, an expression vector as claimed in either of claims 21 or 22, or a host cell as claimed in either of claims 23 or 24.
37. A product comprising cytolytic T-cells reactive against a tumour cell expressing an antigen comprising a polypeptide or protein as claimed in any of  
30 claims 1 to 17, for use in the prophylaxis, therapy or diagnosis of tumours.
38. A product as claimed in claim 37 and obtained or obtainable by a method as claimed in claim 36.

39. A method of treating tumours in a patient comprising administering a composition as claimed in any of claims 29, 30, 31, 33, 37 or 38 to the patient in an amount effective to control or prevent tumour growth.

1/16




Fig.1

2/16



Stimulator cells

Fig. 2

3/16

Sequence cotransfected with HLA-A2.1



TNF released by CTL 447A/5 (pg/ml)





Fig. 3

4/16


Fig. 4a



Peptide concentration (nM)

- CMLLVFGIDV(182 – 191)
- ▲ MLLVFGIDV(183 – 191)

Fig. 4b



Peptide concentration (nM)

- ◆ GLYDGMEHL(254 – 262)
- GLYDGMEHLI(254 – 263)

5/16




Fig. 5

- GLYDGREHS (No Ab)
- GLYDGREHS (MA2.1)
- ◇ GLYDGREHSV (No Ab)
- ◆ GLYDGREHSV (MA2.1)



6/16




Fig. 6

**SEQ ID NO. 1**

MPRAPKRQRCMPEEDLQSQSETQGLEGAQAPLAVEEDASSSTSTSSSFSSFPSSSSSSSSSSCYPLIPS  
TPEEVSADDETPNPPQSAQIACSSPSVVASLPLDQSDGSSSQKEESPSTLQVLPDSESLPRSEIDEKV  
TDLVQFLLFKYQMKEPITKAEILESVIKNYEDHFLLFSEASECMLLVFGIDVKEVDPTGHSFVLVTSL  
GLTYDGMLSDVQSMPKTGILILILSII FIEGYCTPEEVIWEALNMMGLYDGMEHLIYGEPRKLLTQDWV  
QENYLEYRQVPGSDPARYEFLWGPRAHAEIRKMSLLKFLAKVNGSDPRSFPPLWYEEALKDEEERAQDRI  
ATTDDTTAMASASSSATGSFSYPE

**Fig. 7**

8/16

**SEQ ID NO. 2**

MLLGQKSQRYKAE EGLQAQGEAPGLMDVQIPTAEEQKAASSSSTLIMGTLEEVTD SGSPSPPPQSPEGAS  
SSLTVTDSTLWSQSDEGSSSNEEEGPSTSPDPAHLESLFREALDEKVAELVRFLLRKYQIKEPVTKAEM  
LESVIKNYKNHFPDIFSKASECMQVIFGIDVKEVDPAGHSYILVTCLGLSYDGLLGDDQSTPKTGLLII  
VLGMILMEGSRAPEEAIWEALSVMGAV

Fig. 8

Fig. 9

SEQ ID NO. 3

```

1  cagggagatg gtggctttgg cgtgcaagac ccatacacga ttcagcagga gggaaaggct
61  gggctgtcgg gagtaaactct gaatacctgg aggacaccca aataaaggaa gtccccgtct
121 tgtccccctc ccctgcccac ccccccccc ccccccgcga aatgtctgct ccttctgtca
181 gctttgggaa tcccatgcag gtgtgatcgt gtggtgcccc tccccacttc tgcctgcccgg
241 gtctcaggga ggtgaggacc ttggtctgag ggttgctaag aagttattac agggttccac
301 acttgggtcaa cagagggagg agtcccagaa tctgcaggac ccaaggggtg cccccttagt
361 gaggactgga ggtacctgca gccagaaaag aagggatgtc acagagtctg gctgtccctt
421 gttcttagct ctgaggggac ctgatcagga ttggcactaa gtggcaagct caattttacc
481 acaggcagga agatgaggaa ccctcaggga aatggagtgt tggtgtaaag gggagatatc
541 agccctggac accccacagg gatgacagga tgtggctcct tcttactttt gttttggaat
601 ctcaggggagg tgagaacctt gctctcagag ggtgactcaa gtcaacacag ggaacccttc
661 ttttctacag acacagtggg tcgcaggatc tgacaagagt ccaggtaagg aacctgaggg
721 aaatctgagg gtacccccag ccataaacac acccagtcag ggctgtccgc tgagtctccc tgtcttatac
781 ccctactgtc actctggaga acccagtcag ggctgtccgc tgagtctccc tgtcttatac
841 aaggatcact ggtctctggg agggagaggt gttggtctaa gggagctgca ctcgggctag
901 cagagggagg gtcccagacc ctgccaggag tcaaggtgag gactgagggg acaccattct
961 ccaaacgcac aggactcagc cccaccctac cccttctgtc agccacggga attcatgggg
1021 aactgggggt agatggactc ccctcacttc ctctttccat gtctcctgga ggtaggacct
1081 tggtttaagg aagtggcctc agatcaacaa agggagggtc ccaggtcgta tcaggcatca
1141 agaagaggac caagcaggct cctcacccca gtacacatgg acccagctga atatggccac
1201 ctcttgctgt cttttctggg aggacctctg cagttgtggc cagatgtggg tcccctcatg
1261 tcttctatct cgtatcaggg atgtaagctt ttgatctgag agtttcttag accagcaaaag
1321 gagcagggtc taggcttttc caggagaaaag gtgagagccc cagctgagca cagaggctcc
1381 ccaccccagg gtagtgggga actcacagag tccagcccac cctcctgaca aactgggag
1441 gctggggctg tgcttgagc ctgaaccctg agggcccttc aattcctctt tcaggagctc
1501 cagggactgt gaggtgaggc cttggtctaa ggcagtgttt tcaggtcaca gagcagaaag
1561 ggcccagaca gtgccaggag tcaaggtgag gtgcatgccc tgaatgtgta ccaagggccc
1621 cacctgctcc aggacaaagt ggaccccact gcatcagctc cacctaccct actgtcagtc
1681 ctggagcctt ggctctgccc ggctgcatcc tgaggagcca tctctcactt ccttcttcag
1741 gttctcaggg gacagggaga gcaagaggtc aagagctgtg ggacaccaca gagcagcact
1801 gaaggagaag acctgtaagt tggcctttgt tagaacctcc aggggtgtgt tctcagctgt
1861 ggccacttac accctccctc tctcccagg cctgtgggtc cccatcgccc aagtccctgc
1921 cacactccca cctgctacce tgatcagagt catcatgcct cgagctccaa agcgtcagcg
1981 ctgcatgcct gaagaagatc ttcaatccca aagtgagaca cagggcctcg aggggtgcaca
2041 ggctcccctg gctgtggagg aggatgcttc atcatccact tccaccagct cctcttttcc
2101 atcctctttt cctcctcct cctcttcctc ctctcctccc tgctatcctc taataccaag
2161 caccacagag gaggtttctg ctgatgatga gacaccaaat cctccccaga gtgctcagat
2221 agcctgctcc tccccctcgg tcgttgcttc ccttccatta gatcaatctg atgagggtc
2281 cagcagccaa aaggaggaga gtccaagcac cctacagggtc ctgccagaca gtgagtcctt
2341 acccagaagt gagatagatg aaaagggtgac tgatttggtg cagtttctgc tcttcaagta
2401 tcaaatgaag gagccgatca caaaggcaga aatactggag agtgtcataa aaaattatga
2461 agaccacttc cctttgttgt ttagtgaaag ctccgagtgc atgctgctgg tctttggcat
2521 tgatgtaaag gaagtggatc ccactggcca ctcttttgct cttgtcacct ccctgggcct
2581 cacctatgat gggatgctga gtgatgtcca gagcatgccc aagactggca ttctcatact
2641 tatcctaagc ataatcttca tagagggtca ctgcacccct gaggaggtca tctgggaagc
2701 actgaatatg atggggctgt atgatgggat ggagcacctc atttatgggg agcccaggaa
2761 gctgctcacc caagattggg tgcaggaaaa ctacctggag taccggcagg tgcctggcag
2821 tgatcctgca cggatagagt ttctgtgggg tccaagggct catgctgaaa ttaggaagat
2881 gagtctcctg aaatttttgg ccaaggtaaa tgggagtgat ccaagatcct tcccactgtg
2941 gtatgaggag gctttgaaag atgaggaaga gagagcccag gacagaattg ccaccacaga

```

10/16

```
3001 tgatactact gccatggcca gtgcaagttc tagcgctaca ggtagcttct cctaccctga
3061 ataaagtaag acagattctt cactgtgttt taaaaggcaa gtcaaatacc acatgatttt
3121 actcatatgt ggaatctaaa aaaaaaaaaa aaaaaagttg gtatcatgga agtagagagt
3181 agagcagtag ttacattaca attaaatagg aggaataagt tctagtgttc tattgcacag
3241 taggatgact atagttaaca ttaagatatt gtatattaca aaacagctag aaggaaggct
3301 tttcaatatt gtcaccaaaa agaaatgata aatgcatgag gtgatggata cactacctga
3361 tttgatcatt atactacata tacatgaatc agaacatcaa attgtacctc ataaatatct
3421 acaattacat gtcagttttt gtttatgttt ttgttttttt ttaatttatg aaaacaaatg
3481 agaatggaaa tcaatgatgt atgtggtgga
```

Fig. 9 continued

11/16

SEQ ID NO. 4

Fig. 10a

TCCGGGGTCTG	CTCGAGCCGG	CCGGGACTCG	GGGATCASAA	GTAACGGCGG	50
YYMKYGTKCT	GAGGGACAGG	CTTGAGATCG	GCTGAAGAGA	GCGGGCCCAG	100
GCTCTGTGAG	GAGGCAAGGG	AGGTGAGAAC	CTTGCTCTCA	GAGGGTGACT	150
CAAGTCAACA	CAGGGAACCC	CTCTTTTCTA	CAGACACAGT	GGGTCTGCAGG	200
ATCTGACAAG	AGTCCAGGTT	CTCAGGGGAC	AGGGAGAGCA	AGAGGTCAAG	250
AGCTGTGGGA	CACCACAGAG	CAGCACTGAA	GGAGAAGACC	TGCCTGTGGG	300
TCCCCATCGC	CCAAGTCCTG	CCCACACTCC	CACCTGCTAC	CCTGATCAGA	350
GTCATCATGC	CTCGAGCTCC	AAAGCGTCAG	CGCTGCATGC	CTGAAGAAGA	400
TCTTCAATCC	CAAAGTGAGA	CACAGGGCCT	CGAGGGTGCA	CAGGCTCCCC	450
TGGCTGTGGA	GGAGGATGCT	TCATCATCCA	CTTCCACCAG	CTCCTCTTTT	500
CCATCCTCTT	TTCCCTCCTC	CTCCTCTTCC	TCCTCCTCCT	CCTGCTATCC	550
TCTAATACCA	AGCACCCCAG	AGGAGGTTTC	TGCTGATGAT	GAGACACCAA	600
ATCCTCCCCA	GAGTGCTCAG	ATAGCCTGCT	CCTCCCCCTC	GGTCGTTGCT	650
TCCCTTCCAT	TAGATCAATC	TGATGAGGGC	TCCAGCAGCC	AAAAGGAGGA	700
GAGTCCAAGC	ACCCTACAGG	TCCTGCCAGA	CAGTGAGTCT	TTACCCAGAA	750
GTGAGATAGA	TGAAAAGGTG	ACTGATTGG	TGCAGTTTCT	GCTCTTCAAG	800
TATCAAATGA	AGGAGCCGAT	CACAAAGGCA	GAAATACTGG	AGAGTGTCAT	850
AAAAAATTAT	GAAGACCACT	TCCCTTTGTT	GTTTAGTGAA	GCCTCCGAGT	900
GCATGCTGCT	GGTCTTTGGC	ATTGATGTAA	AGGAAGTGGA	TCCCCTGCGC	950
CACTCCTTTG	TCCTTGTCAC	CTCCCTGGGC	CTCACCTATG	ATGGGATGCT	1000
GAGTGATGTC	CAGAGCATGC	CCAAGACTGG	CATTCTCATA	CTTATCCTAA	1050
GCATAATCTT	CATAGAGGGC	TACTGCACCC	CTGAGGAGGT	CATCTGGGAA	1100
GCACTGAATA	TGATGGGGCT	GTATGATGGG	ATGGAGCACC	TCATTTATGG	1150
GGAGCCCAGG	AAGCTGCTCA	CCCAAGATTG	GGTGCAGGAA	AACTACCTGG	1200
AGTACCGGCA	GGTGCCTGGC	AGTGATCCTG	CACGGTATGA	GTTTCTGTGG	1250
GGTCCAAGGG	CTCATGCTGA	AATTAGGAAG	ATGAGTCTCC	TGAAATTTTT	1300
GGCCAAGGTA	AATGGGAGTG	ATCCAAGATC	CTTCCCACTG	TGGTATGAGG	1350
AGGCTTTGAA	AGATGAGGAA	GAGAGAGCCC	AGGACAGAAT	TGCCACCACA	1400
GATGATACTA	CTGCCATGGC	CAGTGCAAGT	TCTAGCGCTA	CAGGTAGCTT	1450
CTCCTACCCT	GAATAAAGTA	AGACAGATTC	TTCCTGTGT	TTTAAAAGGC	1500
AAGTCAAATA	CCACATGATT	TTACTCATAT	GTGGAATCTA	AAAAAAAAAA	1550
AAAAAAAAAGT	TGGTATCATG	GAAGTAGAGA	GTAGAGCAGT	AGTTACATTA	1600
CAATTAAATA	GGAGGAATAA	GTTCTAGTGT	TCTATTGCAC	AGTAGGATGA	1650
CTATAGTTAA	CATTAAGATA	TTGTATATTA	CAAACAGCT	AGAAGGAAGG	1700
CTTTTCAATA	TTGTCACCAA	AAAGAAATGA	TAAATGCATG	AGGTGATGGA	1750

SUBSTITUTE SHEET (RULE 26)

12/16

TACACTACCT	GATGTGATCA	TTATACTACA	TATACATGAA	TCAGAACATC	1800
AAATTGTACC	TCATAAATAT	CTACAATTAC	ATGTCAGTTT	TTGTTTATGT	1850
TTTTGTTTTT	TTTAAATTTA	TGAAAACAAA	TGAGAATGGA	AATCAATGAT	1900
GTATGTGGTG	GAGGGCCAGG	CTGAGGCTGA	GGAAAATACA	GTGCATAACA	1950
TCTTTGTCTT	ACTGTTTTCT	TTGGATAACC	TGGGGACTTC	TTTTCTTTTC	2000
TTCTTGGTAT	TTTATTTTCT	TTTTCTTCTT	CTTCTTTTTT	TTTTTTAACA	2050
AAGTCTCACT	CTATTGCTCT	GGCAGGAGTG	CAGTGGTGCA	GTCTCGGCTC	2100
ACTGCAACTT	CCGCCTCCTG	GGTTC AAGCG	ATTCTCCTGC	CTCAGTCTCC	2150
TGAGTAGCTG	GGATTACAAG	TGTGCACCAC	CATACCCGGC	TAATTTTGTA	2200
TTTTTTAGTA	GAGATGGGGT	TTCACCATGT	TGGCCAGGCT	GGTCTCAAAC	2250
TCCTGACCTC	AGGTAATCTG	CCCGCCTCAG	CCTCCCAAAG	TGCTGGGATA	2300
ACAGGTGTGA	GCCCACTGCA	CCCCAGCCTC	TTCTTGGTAT	TTTAAAATGT	2350
CGTTACTTTT	ACTAGAATGT	TTATGAGCTT	CAGAATCTAA	GGTCACACGT	2400
TCGTTTCTGT	TTATCCAGTT	TAAGAAACAG	TTTTGCTATT	TTGTAAAACA	2450
AATTGGGAAC	CCTTCCATCA	TATTTGTAAT	CTTTAATAAA	ATAACATGGA	2500
ATTGGAATAG	TAATTTTCTT	GGAAATATGA	AAAAATAGTA	AAATAGAGAA	2550
AATAATTTT					2559

Fig. 10b

13/16

SEQ ID NO. 5

Fig. 11a

```

1  agtctcagat cactggagag aggtgcccc gagcccttaa ggaggactca gcagacctcc
61 catcatggcc taggaaacct gctcccactc tcaggtctgg gcaccaagg caggacagtg
121 gggaagggat gtggccccc cactttctgg taggggggcc tcaaggagat ggtggccttg
181 gcatgcaaga cacatccacg gttcagcagg aaggaaaggg ccatgccttg tcgtggagta
241 aatatgaata cctggatgac acccagacag agaaagaccc catgaaacct actacttctg
301 tcagccgtgg gaatcccatg cagggttgct catgtagtgc ctcttactt ctgcctcctg
361 ggtctcaggg aggtagcaac ctgggtctga agggcgctct cagctcagca gagggagcca
421 cacctgttca acagagggac ggggtcacag gatctgcagg acccaagatg tgctcacttt
481 gtgatgaatg ggggtactcc tggcctggaa agaagggacc ccacaaagtc tggctaactt
541 tggttattat ctctggggga acccgatcaa ggggtggcctt aagtggagat ctcatctgta
601 ctgtgggcag gaagttgggg aaacgcagga agataaggtc ttggtggtaa ggggagatgt
661 ctgctcatat cagggtgttg tgggttgagg aagggcgggc tccatcaggg gaaagatgaa
721 taaccccctg aagaccttag aaccaccac tcaagaacaa gtagggacag atcctagtgt
781 caccctgga caccaccacc agtggctatc agatgtggtg gctcctcatt tctctcttga
841 gtctcagggg agtgaggacc ttgttctcag agggcaactc aggacaaaac agggaccccc
901 atgtgggcaa cagactcagt ggtccaagaa tctaccaaga gtctaggtga caacactgag
961 ggaagattga gggtagcctc gatggttctc ctacagaggc aaaaacagat gggggcccaa
1021 cagaaatctg cccggcctct tttgtcacc ctgagagcat gagcaggact atcagctgag
1081 gccctgtgt tataccagac tcattggtct cagggagaag aaggccttgg tctgagggca
1141 ctgcattcag gtcagcagag cgggggtcca aggcctgccc aggagtcagg gactcagagg
1201 acaccactca ccaaacacac aggaccgaac cccaccctgc accttctgtc agccatggga
1261 agtgacaggg aaggtgggtg gatggaatcc cctcatttgc tcttccagtg tctcctggag
1321 ataggtcctt ggattaagga agtggcctca ggtcagccca ggacacatgg gcccacatgt
1381 attttgtgta gctattgctt ttttctcacc ctaggacaga cagtggggcc ccattgcatt
1441 ttgtgtagct attgcttttt tcccaggagg ccttgggcat gtgggggccag atgtgggtcc
1501 ctcatatcc ttgtcttcca tatcagggat ataaactctt gatctgaaag tttctcaggc
1561 cagcaaaagg gccagatcca ggccctgcca ggagaaagat gagggccctg aatgagcaca
1621 gaaaggacca tccacacaaa atagtgggga gctcacagag tcaggctcac cctcctgaca
1681 gcactggggt gctggggctg tgcttgacag ctgcagcctg agttcccctc gatttatctt
1741 ctaggagctc caggaaccag gctgtgaggt cttggtctga ggcagtatct tcaatcacag
1801 agcataagag gcccaggcag tagtagcagt caagctgagg tgggtgttcc cctgtatgta
1861 taccagaggg ccctctggca tcagaacagc aggaacccca cagttcctgg ccctaccagc
1921 ccttttgtca gtccctggagc cttggccttt gccaggaggc tgcaccctga gatgccctct
1981 caatttctcc ttcaggttcg cagagaacag gccagccagg aggtcaggag gcccagaga
2041 agcactgaag aagacctgta agtagacctt tgttagggca tggtaggggt tccagggtgt agtaccagc
2101 tgaggcctct cacacgcttc ctctctccc aggcctgtgg gtctcaattg ccagctccg
2161 gccacactc tctgtctgcc ctgacctgag tcatcatgct tcttgggcag aagagtcagc
2221 gctacaaggc tgaggaaggc cttcaggccc aaggagaggc accagggctt atggatgtgc
2281 agattccac agctgaggag cagaaggctg cctcctctc ctctactctg atcatgggaa
2341 cccttgagga ggtgactgat tctgggtcac caagtcctcc ccagagtcct gaggggtgct
2401 cctcttccct gactgtcacc gacagcactc tgtggagcca atccgatgag ggttccagca
2461 gcaatgaaga ggaggggcca agcacctccc cggaccacgc tcacctggag tccctgttcc
2521 gggaagcact tgatgagaaa gtggctgagt tagttcgttt cctgctccgc aaatatcaaa
2581 ttaaggagcc ggtcacaaa gacagaaatgc ttgagagtgt catcaaaaat tacaagaacc
2641 actttcctga tatcttcagc aaagcctctg agtgcattgca ggtgatcttt ggcattgatg
2701 tgaaggaggt ggaccctgcc ggccactcct acatccttgt cacctgcttg ggcctctcct
2761 atgatggcct gctgggtgat gatcagagta cgcccaagac cggcctcctg ataatcgctc

```



14/16

```
2821 tgggcatgat cttaatggag ggcagccgcg ccccgaggga ggcaatctgg gaagcattga
2881 gtgtgatggg ggctgtatga tgggagggag cacagtgtct attggaagct caggaagctg
2941 ctacaccaag agtgggtgca ggagaactac ctggagtacc gccaggcgcc cggcagtgat
3001 cctgtgcgct acgagttcct gtgggggtcca agggcccttg ctgaaaccag ctatgtgaaa
3061 gtcctggagc atgtgggtcag ggtcaatgca agagttcgca tttcctaccc atccctgcat
3121 gaagaggctt tgggagagga gaaaggagtt tgagcaggag ttgcagctag ggccagtggg
3181 gcaggttgtg ggagggcctg ggccagtgca cgttccaggg ccacatccac cactttccct
3241 gctctgttac atgaggccca ttcttcactc tgtgtttgaa gagagcagtc acagtctctc
3301 gtagtgggga gcatgttggg tgtgagggaa cacagtgtgg accatctctc agttcctggt
3361 ctattgggcg atttggaggt ttatctttgt ttccttttgg aattgttcca atgttccttc
3421 taatggatgg tgtaatgaac ttcaacattc attttatqta tgacagtaga cagacttact
3481 gctttttata tagtttagga gtaagagtct tgcttttcat ttatactggg aaacccatgt
3541 tattttcttga attcagacac tacaagagca gaggattaag gtttttttag aaatgtgaaa
3601 caacatagca gtaaaataca tgagataaag acataaagaa attaaacaat agttaattct
3661 tgccttacct gtacctetta gtgtacccta tgtacctgaa tttgcttggc ttctttgaga
3721 atgaaattga attaaatatg aataaataag tccccctgct cactggctca ttttttccca
3781 aaatattcat tgagcttccg ctattttggaa ggccctgggt tagtattgga gatgctaca
```

Fig. 11b

15/16

## SEQ ID NO. 6

GAGCTCCAGG	AACCAGGCTG	TGAGGTCTTG	GTCTGAGGCA	GTATCTTCAA	50
TCACAGAGCA	TAAGAGGCC	AGGCAGTAGT	AGCAGTCAAG	CTGAGGTGGT	100
GTTTCCCCTG	TATGTATACC	AGAGGCCCTT	CTGGCATCAG	AACAGCAGGA	150
ACCCACAGT	TCCTGGCCCT	ACCAGCCCTT	TTGTCAGTCC	TGGAGCCTTG	200
GCCTTTGCCA	GGAGGCTGCA	CCCTGAGATG	CCCTCTCAAT	TTCTCCTTCA	250
GGTTCCGAGA	GAACAGGCCA	GCCAGGAGGT	CAGGAGGCC	CAGAGAAGCA	300
CTGAAGAAGA	CCTGTAAAGTA	GACCTTTGTT	AGGGCATCCA	GGGTGTAGTA	350
CCCAGCTGAG	GCCTCTCACA	CGCTTCCTCT	CTCCCCAGGC	CTGTGGGTCT	400
CAATTGCCCC	GCTCCGGCCC	ACACTCTCCT	GCTGCCCTGA	CCTGAGTCAT	450
C					451
ATG CTT CTT	GGG CAG AAG	AGT CAG CGC	TAC AAG GCT	GAG GAA	493
GGC CTT CAG	GCC CAA GGA	GAG GCA CCA	GGG CTT ATG	GAT GTG	535
CAG ATT CCC	ACA GCT GAG	GAG CAG AAG	GCT GCA TCC	TCC TCC TCC	577
TCT ACT CTG	ATC ATG GGA	ACC CTT GAG	GAG GTG ACT	GAT TCT	619
GGG TCA CCA	AGT CCT CCC	CAG AGT CCT	GAG GGT GCC	TCC TCT	661
TCC CTG ACT	GTC ACC GAC	AGC ACT CTG	TGG AGC CAA	TCC GAT	703
GAG GGT TCC	AGC AGC AAT	GAA GAG GAG	GGG CCA AGC	ACC TCC	745
CCG GAC CCA	GCT CAC CTG	GAG TCC CTG	TTC CGG GAA	GCA CTT	787
GAT GAG AAA	GTG GCT GAG	TTA GTT CGT	TTC CTG CTC	CGC AAA	829
TAT CAA ATT	AAG GAG CCG	GTC ACA AAG	GCA GAA ATG	CTT GAG	871
AGT GTC ATC	AAA AAT TAC	AAG AAC CAC	TTT CCT GAT	ATC TTC	913
AGC AAA GCC	TCT GAG TGC	ATG CAG GTG	ATC TTT GGC	ATT GAT	955
GTG AAG GAA	GTG GAC CCT	GCC GGC CAC	TCC TAC ATC	CTT GTC	997
ACC TGC CTG	GGC CTC TCC	TAT GAT GGC	CTG CTG GGT	GAT GAT	1039
CAG AGT ACG	CCC AAG ACC	GGC CTC CTG	ATA ATC GTC	CTG GGC	1081
ATG ATC TTA	ATG GAG GGC	AGC CGC GCC	CCG GAG GAG	GCA ATC	1123
TGG GAA GCA	TTG AGT GTG	ATG GGG GCT	GTA TGA		1156
TGGGAGGGAG	CACAGTGTCT	ATTGGAAGCT	CAGGAAGCTG	CTCACCCAAG	1206
AGTGGGTGCA	GGAGAACTAC	CTGGAGTACC	GCCAGGCCCC	CGGCAGTGAT	1256
CCTGTGCGCT	ACGAGTTCCCT	GTGGGGTCCA	AGGGCCCTTG	CTGAAACCAG	1306
CTATGTGAAA	GTCCTGGAGC	ATGTGGTCAG	GGTCAATGCA	AGAGTTCCGA	1356
TTTCCTACCC	ATCCCTGCA	GAAGAGGCTT	TGGGAGAGGA	GAAAGGAGTT	1406
TGAGCAGGAG	TTGCAGCTAG	GGCCAGTGGG	GCAGGTTGTG	GGAGGGCCTG	1456
GGCCAGTGCA	CGTTCCAGGG	CCACATCCAC	CACTTTCCCT	GCTCTGTTAC	1506
ATGAGGCCCA	TTCTTCACTC	TGTGTTTGAA	GAGAGCAGTC	ACAGTTCTCA	1556
GTAGTGGGGA	GCAATGTTGGG	TGTGAGGGAA	CACAGTGTGG	ACCATCTCTC	1606
AGTTCTGTG	CTATTGGGCG	ATTTGGAGGT	TTATCTTTGT	TTCCTTTTGG	1656
AATTGTTCCA	ATGTTCTTTC	TAATGGATGG	TGTAATGAAC	TTCAACATTC	1706
ATTTTATGTA	TGACAGTAGA	CAGACTTACT	GCTTTTATA	TAGTTTAGGA	1756
GTAAGAGTCT	TGCTTTTCAT	TTATACTGGG	AAACCCATGT	TATTTCTTGA	1806
ATTC					1810

Fig. 12

16/16

## SEQ ID NO. 7

ACCTGCTCCA	GGACAAAGTG	GACCCCACTG	CATCAGCTCC	ACCTACCCTA	50
CTGTCAGTCC	TGGAGCCTTG	GCCTCTGCCG	GCTGCATCCT	GAGGAGCCAT	100
CTCTCACTTC	CTTCTTCAGG	TTCTCAGGGG	ACAGGGAGAG	CAAGAGGTCA	150
AGAGCTGTGG	GACACCACAG	AGCAGCACTG	AAGGAGAAGA	CCTGTAAGTT	200
GGCCTTTGTT	AGAACCTCCA	GGGTGTGGTT	CTCAGCTGTG	GCCACTTACA	250
CCCTCCCTCT	CTCCCCAGGC	CTGTGGGTCC	CCATCGCCCA	AGTCCTGCCC	300
ACACTCCAC	CTGCTACCCT	GATCAGAGTC	ATC		333
ATG CCT CGA	GCT CCA AAG	CGT CAG CGC	TGC ATG CCT	GAA GAA	375
GAT CTT CAA	TCC CAA AGT	GAG ACA CAG	GGC CTC GAG	GGT GCA	417
CAG GCT CCC	CTG GCT GTG	GAG GAG GAT	GCT TCA TCA	TCC ACT	459
TCC ACC AGC	TCC TCT TTT	CCA TCC TCT	TTT CCC TCC	TCC TCC	501
TCT TCC TCC	TCC TCC TGC	TAT CCT CTA	ATA CCA AGC	ACC	543
CCA GAG GAG	GTT TCT GCT	GAT GAT GAG	ACA CCA AAT	CCT CCC	585
CAG AGT GCT	CAG ATA GCC	TGC TCC TCC	CCC TCG GTC	GTT GCT	627
TCC CTT CCA	TTA GAT CAA	TCT GAT GAG	GGC TCC AGC	AGC CAA	669
AAG GAG GAG	AGT CCA AGC	ACC CTA CAG	GTC CTG CCA	GAC AGT	711
GAG TCT TTA	CCC AGA AGT	GAG ATA GAT	GAA AAG GTG	ACT GAT	753
TTG GTG CAG	TTT CTG CTC	TTC AAG TAT	CAA ATG AAG	GAG CCG	795
ATC ACA AAG	GCA GAA ATA	CTG GAG AGT	GTC ATA AAA	AAT TAT	837
GAA GAC CAC	TTC CCT TTG	TTG TTT AGT	GAA GCC TCC	GAG TGC	879
ATG CTG CTG	GTC TTT GGC	ATT GAT GTA	AAG GAA GTG	GAT CC	920

Fig. 13

-1-

## SEQUENCE LISTING

&lt;110&gt; Ludwig Institute For Cancer Research

&lt;120&gt; Tumour rejection antigens

&lt;130&gt; TSJ/34953

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; GB 9826143.1

&lt;151&gt; 1998-11-27

&lt;160&gt; 56

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 369

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

Met	Pro	Arg	Ala	Pro	Lys	Arg	Gln	Arg	Cys	Met	Pro	Glu	Glu	Asp	Leu
1				5					10					15	

Gln	Ser	Gln	Ser	Glu	Thr	Gln	Gly	Leu	Glu	Gly	Ala	Gln	Ala	Pro	Leu
			20					25					30		

Ala	Val	Glu	Glu	Asp	Ala	Ser	Ser	Ser	Thr	Ser	Thr	Ser	Ser	Ser	Phe
		35					40					45			

Pro	Ser	Ser	Phe	Pro	Ser	Ser	Ser	Ser	Ser	Ser	Ser	Ser	Ser	Cys	Tyr
	50					55						60			

Pro	Leu	Ile	Pro	Ser	Thr	Pro	Glu	Glu	Val	Ser	Ala	Asp	Asp	Glu	Thr
	65				70					75					80

Pro	Asn	Pro	Pro	Gln	Ser	Ala	Gln	Ile	Ala	Cys	Ser	Ser	Pro	Ser	Val
				85					90					95	

Val	Ala	Ser	Leu	Pro	Leu	Asp	Gln	Ser	Asp	Glu	Gly	Ser	Ser	Ser	Gln
			100					105					110		

Lys	Glu	Glu	Ser	Pro	Ser	Thr	Leu	Gln	Val	Leu	Pro	Asp	Ser	Glu	Ser
		115					120					125			

Leu	Pro	Arg	Ser	Glu	Ile	Asp	Glu	Lys	Val	Thr	Asp	Leu	Val	Gln	Phe
	130					135					140				

Leu	Leu	Phe	Lys	Tyr	Gln	Met	Lys	Glu	Pro	Ile	Thr	Lys	Ala	Glu	Ile
145					150					155					160

-2-

Leu Glu Ser Val Ile Lys Asn Tyr Glu Asp His Phe Pro Leu Leu Phe  
 165 170 175  
 Ser Glu Ala Ser Glu Cys Met Leu Leu Val Phe Gly Ile Asp Val Lys  
 180 185 190  
 Glu Val Asp Pro Thr Gly His Ser Phe Val Leu Val Thr Ser Leu Gly  
 195 200 205  
 Leu Thr Tyr Asp Gly Met Leu Ser Asp Val Gln Ser Met Pro Lys Thr  
 210 215 220  
 Gly Ile Leu Ile Leu Ile Leu Ser Ile Ile Phe Ile Glu Gly Tyr Cys  
 225 230 235 240  
 Thr Pro Glu Glu Val Ile Trp Glu Ala Leu Asn Met Met Gly Leu Tyr  
 245 250 255  
 Asp Gly Met Glu His Leu Ile Tyr Gly Glu Pro Arg Lys Leu Leu Thr  
 260 265 270  
 Gln Asp Trp Val Gln Glu Asn Tyr Leu Glu Tyr Arg Gln Val Pro Gly  
 275 280 285  
 Ser Asp Pro Ala Arg Tyr Glu Phe Leu Trp Gly Pro Arg Ala His Ala  
 290 295 300  
 Glu Ile Arg Lys Met Ser Leu Leu Lys Phe Leu Ala Lys Val Asn Gly  
 305 310 315 320  
 Ser Asp Pro Arg Ser Phe Pro Leu Trp Tyr Glu Glu Ala Leu Lys Asp  
 325 330 335  
 Glu Glu Glu Arg Ala Gln Asp Arg Ile Ala Thr Thr Asp Asp Thr Thr  
 340 345 350  
 Ala Met Ala Ser Ala Ser Ser Ser Ala Thr Gly Ser Phe Ser Tyr Pro  
 355 360 365

Glu

&lt;210&gt; 2

&lt;211&gt; 234

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Met Leu Leu Gly Gln Lys Ser Gln Arg Tyr Lys Ala Glu Glu Gly Leu  
 1 5 10 15

Gln Ala Gln Gly Glu Ala Pro Gly Leu Met Asp Val Gln Ile Pro Thr  
 20 25 30

-3-

Ala Glu Glu Gln Lys Ala Ala Ser Ser Ser Ser Thr Leu Ile Met Gly  
                   35                                  40                                  45

Thr Leu Glu Glu Val Thr Asp Ser Gly Ser Pro Ser Pro Pro Gln Ser  
           50                                  55                                  60

Pro Glu Gly Ala Ser Ser Ser Leu Thr Val Thr Asp Ser Thr Leu Trp  
   65                                  70                                  75                                  80

Ser Gln Ser Asp Glu Gly Ser Ser Ser Asn Glu Glu Glu Gly Pro Ser  
                   85                                  90                                  95

Thr Ser Pro Asp Pro Ala His Leu Glu Ser Leu Phe Arg Glu Ala Leu  
                   100                                  105                                  110

Asp Glu Lys Val Ala Glu Leu Val Arg Phe Leu Leu Arg Lys Tyr Gln  
           115                                  120                                  125

Ile Lys Glu Pro Val Thr Lys Ala Glu Met Leu Glu Ser Val Ile Lys  
   130                                  135                                  140

Asn Tyr Lys Asn His Phe Pro Asp Ile Phe Ser Lys Ala Ser Glu Cys  
  145                                  150                                  155                                  160

Met Gln Val Ile Phe Gly Ile Asp Val Lys Glu Val Asp Pro Ala Gly  
                   165                                  170                                  175

His Ser Tyr Ile Leu Val Thr Cys Leu Gly Leu Ser Tyr Asp Gly Leu  
                   180                                  185                                  190

Leu Gly Asp Asp Gln Ser Thr Pro Lys Thr Gly Leu Leu Ile Ile Val  
   195                                  200                                  205

Leu Gly Met Ile Leu Met Glu Gly Ser Arg Ala Pro Glu Glu Ala Ile  
   210                                  215                                  220

Trp Glu Ala Leu Ser Val Met Gly Ala Val  
  225                                  230

&lt;210&gt; 3

&lt;211&gt; 3510

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1955)..(3064)

&lt;400&gt; 3

cagggagatg gtggcttttg cgtgcaagac ccatacacga ttcagcagga gggaaaggct 60  
 gggctgtcgg gagtaaactt gaatacctgg aggacaccca aataaaggaa gtccccgtct 120  
 tgtccccctc cctgcccac ccccccccc ccccccgcca aatgtctgct ccttctgtca 180

-4-

```

gctttgggaa tcccatgcag gtgtgatcgt gtggtgcccc tccccacttc tgcctgccgg 240
gtctcagggg ggtgaggacc ttggtctgag gggttgctaag aagttattac aggggtccac 300
acttggtcaa cagagggagg agtcccagaa tctgcaggac ccaaggggtg ccccttagt 360
gaggactgga ggtacctgca gccagaaaag aagggatgtc acagagtctg gctgtcccct 420
gttcttagct ctgaggggac ctgatcagga ttggcactaa gtggcaagct caattttacc 480
acaggcagga agatgaggaa ccctcagggg aatggagtgt tggtgtaaag gggagatata 540
agccctggac accccacagg gatgacagga tgtggctcct tcttactttt gttttggaat 600
ctcagggagg tgagaacctt gctctcagag ggtgactcaa gtcaacacag ggaacccctc 660
ttttctacag acacagtggg tcgcaggatc tgacaagagt ccaggtaagg aacctgaggg 720
aaatctgagg gtacccccag ccataaacac agatgggggt cccacagaaa tctgccatga 780
ccctactgtc actctggaga acccagtcag ggctgtccgc tgagtctccc tgtcttatac 840
aaggatcact ggtctctggg agggagaggt gttggtctaa gggagctgca ctcgggtcag 900
cagagggagg gtcccagacc ctgccaggag tcaaggtgag gactgagggg acaccattct 960
ccaaacgcac aggactcagc cccaccctac ccttctgtc agccacggga attcatgggg 1020
aactgggggt agatggactc ccctcacttc ctcttccat gtctcctgga ggtaggacct 1080
tggtttaagg aagtggcctc agatcaacaa agggaggggt ccaggtcgta tcaggcatca 1140
agaagaggac caagcaggct cctcacccca gtacacatgg acccagctga atatggccac 1200
ctcttgctgt cttttctggg aggacctctg cagttgtggc cagatgtggg tcccctcatg 1260
tcttctatct cgtatcaggg atgtaagctt ttgatctgag agtttcttag accagcaaag 1320
gagcaggggt taggcttttc caggagaaag gtgagagccc cacgtgagca cagaggctcc 1380
ccacccccagg gtagtgggga actcacagag tccagcccac cctcctgaca aactggggag 1440
gctggggctg tgcttgacgc ctgaacctg agggcccctc aattcctctt tcaggagctc 1500
cagggactgt gaggtgaggg cttggtctaa ggcagtgttt tcaggtcaca gacagaaaag 1560
ggcccagaca gtgccaggag tcaagggtgag gtgcatgccc tgaatgtgta ccaagggccc 1620
cacctgctcc aggacaaagt ggacccact gcatcagctc cacctaccct actgtcagtc 1680
ctggagcctt ggctctgccc ggctgcatcc tgaggagcca tctctcactt ccttcttcag 1740
gttctcaggg gacagggaga gcaagaggtc aagagctgtg ggacaccaca gagcagcact 1800
gaaggagaag acctgtaagt tggcctttgt tagaacctcc aggggtgtgt tctcagctgt 1860
ggccacttac accctccctc tctccccagg cctgtgggtc cccatcgccc aagtctgccc 1920

cacactccca cctgctaccc tgatcagagt catc atg cct cga gct cca aag cgt 1975
Met Pro Arg Ala Pro Lys Arg
1 5

cag cgc tgc atg cct gaa gaa gat ctt caa tcc caa agt gag aca cag 2023
Gln Arg Cys Met Pro Glu Glu Asp Leu Gln Ser Gln Ser Glu Thr Gln
10 15 20

ggc ctc gag ggt gca cag gct ccc ctg gct gtg gag gag gat gct tca 2071
Gly Leu Glu Gly Ala Gln Ala Pro Leu Ala Val Glu Glu Asp Ala Ser
25 30 35

tca tcc act tcc acc agc tcc tct ttt cca tcc tct ttt ccc tcc tcc 2119
Ser Ser Thr Ser Thr Ser Ser Ser Phe Pro Ser Ser Phe Pro Ser Ser
40 45 50 55

tcc tct tcc tcc tcc tcc tcc tgc tat cct cta ata cca agc acc cca 2167
Ser Ser Ser Ser Ser Ser Ser Cys Tyr Pro Leu Ile Pro Ser Thr Pro
60 65 70

gag gag gtt tct gct gat gat gag aca cca aat cct ccc cag agt gct 2215
Glu Glu Val Ser Ala Asp Asp Glu Thr Pro Asn Pro Pro Gln Ser Ala
75 80 85

```

-5-

cag ata gcc tgc tcc tcc ccc tcg gtc gtt gct tcc ctt cca tta gat	2263
Gln Ile Ala Cys Ser Ser Pro Ser Val Val Ala Ser Leu Pro Leu Asp	
90 95 100	
caa tct gat gag ggc tcc agc agc caa aag gag gag agt cca agc acc	2311
Gln Ser Asp Glu Gly Ser Ser Ser Gln Lys Glu Glu Ser Pro Ser Thr	
105 110 115	
cta cag gtc ctg cca gac agt gag tct tta ccc aga agt gag ata gat	2359
Leu Gln Val Leu Pro Asp Ser Glu Ser Leu Pro Arg Ser Glu Ile Asp	
120 125 130 135	
gaa aag gtg act gat ttg gtg cag ttt ctg ctc ttc aag tat caa atg	2407
Glu Lys Val Thr Asp Leu Val Gln Phe Leu Phe Lys Tyr Gln Met	
140 145 150	
aag gag ccg atc aca aag gca gaa ata ctg gag agt gtc ata aaa aat	2455
Lys Glu Pro Ile Thr Lys Ala Glu Ile Leu Glu Ser Val Ile Lys Asn	
155 160 165	
tat gaa gac cac ttc cct ttg ttg ttt agt gaa gcc tcc gag tgc atg	2503
Tyr Glu Asp His Phe Pro Leu Leu Phe Ser Glu Ala Ser Glu Cys Met	
170 175 180	
ctg ctg gtc ttt ggc att gat gta aag gaa gtg gat ccc act ggc cac	2551
Leu Leu Val Phe Gly Ile Asp Val Lys Glu Val Asp Pro Thr Gly His	
185 190 195	
tcc ttt gtc ctt gtc acc tcc ctg ggc ctc acc tat gat ggg atg ctg	2599
Ser Phe Val Leu Val Thr Ser Leu Gly Leu Thr Tyr Asp Gly Met Leu	
200 205 210 215	
agt gat gtc cag agc atg ccc aag act ggc att ctc ata ctt atc cta	2647
Ser Asp Val Gln Ser Met Pro Lys Thr Gly Ile Leu Ile Leu Ile Leu	
220 225 230	
agc ata atc ttc ata gag ggc tac tgc acc cct gag gag gtc atc tgg	2695
Ser Ile Ile Phe Ile Glu Gly Tyr Cys Thr Pro Glu Glu Val Ile Trp	
235 240 245	
gaa gca ctg aat atg atg ggg ctg tat gat ggg atg gag cac ctc att	2743
Glu Ala Leu Asn Met Met Gly Leu Tyr Asp Gly Met Glu His Leu Ile	
250 255 260	
tat ggg gag ccc agg aag ctg ctc acc caa gat tgg gtg cag gaa aac	2791
Tyr Gly Glu Pro Arg Lys Leu Leu Thr Gln Asp Trp Val Gln Glu Asn	
265 270 275	
tac ctg gag tac cgg cag gtg cct ggc agt gat cct gca cgg tat gag	2839
Tyr Leu Glu Tyr Arg Gln Val Pro Gly Ser Asp Pro Ala Arg Tyr Glu	
280 285 290 295	



gtgtttttaaa	aggcaagtca	aataccacat	gattttactc	atatgtggaa	tctaaaaaaaa	3144
aaaaaaaaaaa	aagttggtat	catggaagta	gagagtagag	cagtagttac	attacaatta	3204
aataggagga	ataagttcta	gtgttctatt	gcacagtagg	atgactatag	ttaacattaa	3264
gatattgtat	attacaaaac	agctagaagg	aaggcttttc	aatattgtca	ccaaaaagaa	3324
atgataaatg	catgaggtga	tggatacact	acctgatttg	atcattatac	tacatatata	3384
tgaatcagaa	catcaaattg	tacctcataa	atatctacaa	ttacatgtca	gtttttgttt	3444
atgtttttgt	ttttttttta	tttatgaaaa	caaatgagaa	tggaaatcaa	tgatgtatgt	3504
qqtqqa						3510

```
<210> 4
<211> 2559
<212> DNA
<213> Homo sapiens
```

<400> 4							
tccgggggtcg	ctcgagccgg	cggggactcg	gggatcasaa	gtaacggcgg	ymkygtkct	60	
gagggacagg	cttgagatcg	gctgaagaga	gcgggcccag	gctctgtgag	gaggcaagg	120	
aggtgagaac	cttgctctca	gagggtgact	caagtcaaca	caggggaacc	ctcttttcta	180	
cagacacagt	gggtcgcagg	atctgacaag	agtccaggtt	ctcaggggac	agggagagca	240	
agaggtcaag	agctgtggga	caccacagag	cagcactgaa	ggagaagacc	tgctctgtgg	300	
tccccatcgc	ccaagtcctg	cccacactcc	cacctgctac	cctgatcaga	gtcatcatgc	360	
ctcaggtccc	aaagcgtcag	cgtctcatgc	ctgaagaaga	tcttcaatcc	caaagtgaga	420	
cacagggcct	cgaggggtgca	caggctcccc	tggctgtgga	ggaggatgct	tcatcatcca	480	
cttccaccag	ctcctctttt	ccatcctctt	ttccctctct	ctcctcttcc	tctcctcct	540	
cctgctatcc	tctaatacca	agcacccccag	aggagggttt	tgctgatgat	gagacaccaa	600	
atcctcccca	gagtgtctcag	atagcctgct	cctccccctc	ggtcgttgct	tcccttccat	660	
tagatcaatc	tgatgagggc	tccagcagcc	aaaaggagga	gagtccaagc	accctacagg	720	
tctctgccaga	cagtgaagtct	ttaccacagaa	gtgagataga	tgaaaagggt	actgatttgg	780	
tcgagtttct	gctcttcaag	tatcaaatag	aggagccgat	cacaaaaggca	gaaatacttg	840	
agagtgatcat	aaaaaatttat	gaagaccact	tccctttgtt	gttttagtgaa	gcctccgagt	900	
gcatgtctgct	ggtctttggc	attgatgtaa	aggaagtgga	tcccactggc	cactcctttg	960	

-7-

```

tccttggtcac ctccctgggc ctcacctatg atgggatgct gagtgatgtc cagagcatgc 1020
ccaagactgg cattctcata cttatcctaa gcataatctt catagagggc tactgcaccc 1080
ctgaggagggt catctgggaa gcactgaata tgatggggct gtatgatggg atggagcacc 1140
tcattttatgg ggagcccagg aagctgctca cccaagattg ggtgcaggaa aactacctgg 1200
agtaccggca ggtgectggc agtgatcctg cacggtatga gtttctgtgg ggtccaaggg 1260
ctcatgctga aattaggaag atgagtcctc tgaaattttt ggccaaggta aatgggagtg 1320
atccaagatc cttcccactg tggatgagg aggccttgaa agatgaggaa gagagagccc 1380
aggacagaat tgccaccaca gatgatacta ctgccatggc cagtgcaggt tctagcgcta 1440
caggtagctt ctcctaccct gaataaagta agacagattc ttcactgtgt tttaaaaggc 1500
aagtcaaata ccacatgatt ttactcatat gtggaatcta aaaaaaaaaa aaaaaaaagt 1560
tggatcatg gaagtagaga gtagagcagt agttacatta caattaaata ggaggaataa 1620
gttctagtgt tctattgcac agtaggatga ctatagttaa cattaagata ttgtatatta 1680
caaaacagct agaaggaagg cttttcaata ttgtcaccaa aaagaaatga taaatgcatg 1740
aggtgatgga tacactacct gatgtgatca ttatactaca tatacatgaa tcagaacatc 1800
aaattgtacc tcataaatat ctacaattac atgtcagttt ttgtttatgt ttttgttttt 1860
ttttaattta tgaaaacaaa tgagaatgga aatcaatgat gtatgtggtg gagggccagg 1920
ctgaggctga ggaaaataca gtgcataaca tctttgtctt actgttttct ttggataacc 1980
tggggacttc ttttcttttc ttcttggtat tttattttct ttttcttctt cttctttttt 2040
ttttttaaca aagtctcact ctattgctct ggcaggagtg cagtggtgca gtctcggtc 2100
actgcaactt ccgcctcctg ggttcaagcg attctcctgc ctcagtcctc tgagtagctg 2160
ggattacaag tgtgcaccac catacccggc taattttgta ttttttagta gagatgggg 2220
ttcaccatgt tggccaggct ggtctcaaac tctgcacctc aggtaatctg ccgcctcag 2280
cctcccaaag tgctgggata acaggtgtga gccactgca cccagcctc ttcttggtat 2340
tttaaaatgt tgttactttt actagaatgt ttatgagctt cagaatctaa ggtcacacgt 2400
tcgtttctgt ttatccagtt taagaaacag ttttgctatt ttgtaaaaca aattgggaac 2460
ccttccatca tatttgtaat ctttaataaaa ataacatgga attggaatag taattttctt 2520
ggaaatatga aaaaatagta aaatagagaa aataatttt 2559

```

&lt;210&gt; 5

&lt;211&gt; 3839

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (2196) .. (2900)

&lt;400&gt; 5

```

agtctcagat cactggagag aggtgcccc aagcccttaa ggaggactca gcagacctcc 60
catcatggcc taggaaacct gctcccactc tcagggtctgg gcaccaagg caggacagtg 120
gggaagggat gtggccccc cactttctgg tagggggggc tcaaggagat ggtggccttg 180
gcatgcaaga cacatccacg gttcagcagg aaggaaaggg ccatgccttg tcgtggagta 240
aatatgaata cctggatgac acccagacag agaaagacct catgaaacct actacttctg 300
tcagccgtgg gaatcccatg cagggttgct catgtagtgc ctcttactt ctgcctcctg 360
ggtctcaggg aggtagcaac ctgggtctga agggcgctct cagctcagca gagggagcca 420
cacctgttca acagaggagc ggggtcacag gatctgcagg acccaagatg tgctcacttt 480
gtgatgaatg ggggtactcc tggcctggaa agaagggacc ccacaaagtc tggttaactt 540
tggttattat ctctggggga acccgatcaa ggggtggcct aagtggagat ctcatctgta 600
ctgtgggcag gaagtgggg aaacgcagga agataaggct ttggtggtta ggggagatgt 660
ctgctcatat cagggtgttg tgggttgagg aaggcgggc tccatcaggg gaaagatgaa 720
taaccccctg aagaccttag aaccaccac tcaagaacaa gtagggacag atcctagtgt 780
caccctgga caccacccc agtggtcatc agatgtggtg gtcctcatt tctctcttga 840
gtctcaggg aagtgaggacc ttgttctcag agggcaactc aggacaaaac agggaccccc 900

```

-8-

atgtgggcaa	cagactcagt	ggtccaagaa	tctaccaaga	gtctaggtga	caacactgag	960
ggaagattga	gggtaccctc	gatggttctc	ctagcaggca	aaaaacagat	gggggcccac	1020
cagaaatctg	cccggcctct	tttgtcacc	ctgagagcat	gagcaggact	atcagctgag	1080
gcccctgtgt	tataccagac	tcattggtct	cagggagaag	aaggccttgg	tctgagggca	1140
ctgcatttcag	gtcagcagag	cgggggtcca	aggccctgcc	aggagtcagg	gactcagagg	1200
acaccactca	ccaaacacac	aggaccgaac	cccaccctgc	accttctgtc	agccatggga	1260
agtgcaggga	aaggtgggtg	gatggaatcc	cctcatttgc	tcttccagtg	tctcctggag	1320
ataggtcctt	ggattaagga	agtggcctca	ggtcagccca	ggacacatgg	gccccaatgt	1380
atattgtgta	gctattgctt	ttttctcacc	ctaggacaga	cacgtggggc	ccattgcatt	1440
ttgtgtagct	attgcttttt	tcccaggagg	ccttggggcat	gtgggggccag	atgtgggtcc	1500
cttcataatcc	ttgtcttcca	tatcagggat	ataaactctt	gatctgaaag	tttctcaggc	1560
cagcaaaagg	gccagatcca	ggccctgcc	ggagaaagat	gagggccctg	aatgagcaca	1620
gaaaggacca	tccacacaaa	atagtgggga	gctcacagag	tcaggctcac	cctcctgaca	1680
gcaactgggtg	gctggggctg	tgcttgagct	ctgcagcctg	agttcccttc	gatttatctt	1740
ctaggagctc	caggaaccag	gctgtgaggt	cttggtctga	ggcagtatct	tcaatcacag	1800
agcataagag	gccagggcag	tagtagcagt	caagctgagg	tggtgtttcc	cctgtatgta	1860
taccagaggc	ccctctggca	tcagaacagc	aggaacccca	cagttcctgg	ccctaccagc	1920
cctttttgtca	gtcctggagc	cttggccttt	gccaggaggc	tgacccctga	gatgccctct	1980
caatttctcc	ttcagggttcg	cagagaacag	gccagccagg	aggtcaggag	gccccagaga	2040
agcactgaag	aagacctgta	agtagacctt	tgtaggggca	tccagggtgt	agtaccagc	2100
tgaggcctct	cacacgcttc	ctctctcccc	aggcctgtgg	gtctcaattg	cccagctccg	2160
gcccacactc tctgtctgcc ctgacctgag tcatc atg ctt ctt ggg cag aag						2213
Met Leu Leu Gly Gln Lys						
1 5						
agt cag cgc tac aag gct gag gaa ggc ctt cag gcc caa gga gag gca						2261
Ser Gln Arg Tyr Lys Ala Glu Glu Gly Leu Gln Ala Gln Gly Glu Ala						
10 15 20						
cca ggg ctt atg gat gtg cag att ccc aca gct gag gag cag aag gct						2309
Pro Gly Leu Met Asp Val Gln Ile Pro Thr Ala Glu Glu Gln Lys Ala						
25 30 35						
gca tcc tcc tcc tct act ctg atc atg gga acc ctt gag gag gtg act						2357
Ala Ser Ser Ser Ser Thr Leu Ile Met Gly Thr Leu Glu Glu Val Thr						
40 45 50						
gat tct ggg tca cca agt cct ccc cag agt cct gag ggt gcc tcc tct						2405
Asp Ser Gly Ser Pro Ser Pro Pro Gln Ser Pro Glu Gly Ala Ser Ser						
55 60 65 70						
tcc ctg act gtc acc gac agc act ctg tgg agc caa tcc gat gag ggt						2453
Ser Leu Thr Val Thr Asp Ser Thr Leu Trp Ser Gln Ser Asp Glu Gly						
75 80 85						
tcc agc agc aat gaa gag gag ggg cca agc acc tcc ccg gac cca gct						2501
Ser Ser Ser Asn Glu Glu Glu Gly Pro Ser Thr Ser Pro Asp Pro Ala						
90 95 100						
cac ctg gag tcc ctg ttc cgg gaa gca ctt gat gag aaa gtg gct gag						2549
His Leu Glu Ser Leu Phe Arg Glu Ala Leu Asp Glu Lys Val Ala Glu						
105 110 115						

-9-

tta gtt cgt ttc ctg ctc cgc aaa tat caa att aag gag ccg gtc aca 2597  
 Leu Val Arg Phe Leu Leu Arg Lys Tyr Gln Ile Lys Glu Pro Val Thr  
 120 125 130

aag gca gaa atg ctt gag agt gtc atc aaa aat tac aag aac cac ttt 2645  
 Lys Ala Glu Met Leu Glu Ser Val Ile Lys Asn Tyr Lys Asn His Phe  
 135 140 145 150

cct gat atc ttc agc aaa gcc tct gag tgc atg cag gtg atc ttt ggc 2693  
 Pro Asp Ile Phe Ser Lys Ala Ser Glu Cys Met Gln Val Ile Phe Gly  
 155 160 165

att gat gtg aag gaa gtg gac cct gcc ggc cac tcc tac atc ctt gtc 2741  
 Ile Asp Val Lys Glu Val Asp Pro Ala Gly His Ser Tyr Ile Leu Val  
 170 175 180

acc tgc ctg ggc ctc tcc tat gat ggc ctg ctg ggt gat gat cag agt 2789  
 Thr Cys Leu Gly Leu Ser Tyr Asp Gly Leu Leu Gly Asp Asp Gln Ser  
 185 190 195

acg ccc aag acc ggc ctc ctg ata atc gtc ctg ggc atg atc tta atg 2837  
 Thr Pro Lys Thr Gly Leu Leu Ile Ile Val Leu Gly Met Ile Leu Met  
 200 205 210

gag ggc agc cgc gcc ccg gag gag gca atc tgg gaa gca ttg agt gtg 2885  
 Glu Gly Ser Arg Ala Pro Glu Glu Ala Ile Trp Glu Ala Leu Ser Val  
 215 220 225 230

atg ggg gct gta tga tgggagggag cacagtgtct attggaagct caggaagctg 2940  
 Met Gly Ala Val  
 235

ctcaccceaag agtgggtgca ggagaactac ctggagtacc gccaggcgcc cggcagtgat 3000  
 cctgtgcgct acgagttcct gtgggggtcca agggcccttg ctgaaaccag ctatgtgaaa 3060  
 gtcctggagc atgtggtcag ggtcaatgca agagttcgca ttctctaccc atccctgcat 3120  
 gaagaggctt tgggagagga gaaaggagtt tgagcaggag ttgcagctag ggccagtggt 3180  
 gcaggttgtg ggagggcctg ggccagtgca cgttcaggag ccacatccac cactttccct 3240  
 gctctgttac atgaggccca ttcttcactc tgtgtttgaa gagagcagtc acagttctca 3300  
 gtagtgggga gcatgttggg tgtgagggaa cacagtgtgg accatctctc agttcctgtt 3360  
 ctattgggag atttgagggt ttatctttgt ttcttttttg aattgttcca atgttccttc 3420  
 taatggatgg tgtaatgaac ttcaacattc attttatgta tgacagtaga cagacttact 3480  
 gctttttata tagtttagga gtaagagtct tgcttttcat ttatactggg aaacccatgt 3540  
 tatttcttga attcagacac tacaagagca gaggattaag gtttttttag aaatgtgaaa 3600  
 caacatagca gtaaaatata tgagataaag acataaagaa attaaacaat agttaattct 3660  
 tgccttacct gtacctctta gtgtacccta tgtacctgaa tttgcttggc ttctttgaga 3720  
 atgaaattga attaaatatg aataaataag tccccctgct cactggctca ttttttccca 3780  
 aaatattcat tgagcttccg ctatttgga ggccctgggt tagtattgga gatgctaca 3839

&lt;210&gt; 6

&lt;211&gt; 1810

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

-10-

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (452)..(1153)

&lt;400&gt; 6

```

gagctccagg aaccaggctg tgaggctctg gtctgaggca gtatcttcaa tcacagagca 60
taagaggccc aggcagtagt agcagtcaag ctgagggtgg gtttcccctg tatgtatacc 120
agaggcccct ctggcatcag aacagcagga accccacagt tcctggccct accagccctt 180
ttgtcagtec tggagccttg gcctttgccca ggaggctgca ccctgagatg ccctctcaat 240
ttctccttca ggttcgcaga gaacaggcca gccaggaggt caggaggccc cagagaagca 300
ctgaagaaga cctgtaagta gacctttgtt agggcatcca ggggtgtagta cccagctgag 360
gcctctcaca cgcttcctct ctccccaggc ctgtgggtct caattgccca gtcocggccc 420

```

```

acactctcct gctgcctga cctgagtcac c atg ctt ctt ggg cag aag agt      472
                               Met Leu Leu Gly Gln Lys Ser
                               1                               5

```

```

cag cgc tac aag gct gag gaa ggc ctt cag gcc caa gga gag gca cca      520
Gln Arg Tyr Lys Ala Glu Glu Gly Leu Gln Ala Gln Gly Glu Ala Pro
                10                15                20

```

```

ggg ctt atg gat gtg cag att ccc aca gct gag gag cag aag gct gca      568
Gly Leu Met Asp Val Gln Ile Pro Thr Ala Glu Glu Gln Lys Ala Ala
                25                30                35

```

```

tcc tcc tcc tct act ctg atc atg gga acc ctt gag gag gtg act gat      616
Ser Ser Ser Ser Thr Leu Ile Met Gly Thr Leu Glu Glu Val Thr Asp
                40                45                50                55

```

```

tct ggg tca cca agt cct ccc cag agt cct gag ggt gcc tcc tct tcc      664
Ser Gly Ser Pro Ser Pro Pro Gln Ser Pro Glu Gly Ala Ser Ser Ser
                60                65                70

```

```

ctg act gtc acc gac agc act ctg tgg agc caa tcc gat gag ggt tcc      712
Leu Thr Val Thr Asp Ser Thr Leu Trp Ser Gln Ser Asp Glu Gly Ser
                75                80                85

```

```

agc agc aat gaa gag gag ggg cca agc acc tcc ccg gac cca gct cac      760
Ser Ser Asn Glu Glu Glu Gly Pro Ser Thr Ser Pro Asp Pro Ala His
                90                95                100

```

```

ctg gag tcc ctg ttc cgg gaa gca ctt gat gag aaa gtg gct gag tta      808
Leu Glu Ser Leu Phe Arg Glu Ala Leu Asp Glu Lys Val Ala Glu Leu
                105                110                115

```

```

gtt cgt ttc ctg ctc cgc aaa tat caa att aag gag ccg gtc aca aag      856
Val Arg Phe Leu Leu Arg Lys Tyr Gln Ile Lys Glu Pro Val Thr Lys
                120                125                130                135

```

```

gca gaa atg ctt gag agt gtc atc aaa aat tac aag aac cac ttt cct      904
Ala Glu Met Leu Glu Ser Val Ile Lys Asn Tyr Lys Asn His Phe Pro
                140                145                150

```

-11-

```

gat atc ttc agc aaa gcc tct gag tgc atg cag gtg atc ttt ggc att 952
Asp Ile Phe Ser Lys Ala Ser Glu Cys Met Gln Val Ile Phe Gly Ile
                155                      160                      165

gat gtg aag gaa gtg gac cct gcc ggc cac tcc tac atc ctt gtc acc 1000
Asp Val Lys Glu Val Asp Pro Ala Gly His Ser Tyr Ile Leu Val Thr
                170                      175                      180

tgc ctg ggc ctc tcc tat gat ggc ctg ctg ggt gat gat cag agt acg 1048
Cys Leu Gly Leu Ser Tyr Asp Gly Leu Leu Gly Asp Asp Gln Ser Thr
                185                      190                      195

ccc aag acc ggc ctc ctg ata atc gtc ctg ggc atg atc tta atg gag 1096
Pro Lys Thr Gly Leu Leu Ile Ile Val Leu Gly Met Ile Leu Met Glu
200                      205                      210                      215

ggc agc cgc gcc ccg gag gag gca atc tgg gaa gca ttg agt gtg atg 1144
Gly Ser Arg Ala Pro Glu Glu Ala Ile Trp Glu Ala Leu Ser Val Met
                220                      225                      230

ggg gct gta tgatgggagg gagcacagtg tctattggaa gctcaggaag 1193
Gly Ala Val

ctgctcacc cagagtgagg gcaggagaa tacctggagt accgccagg gcccggcagt 1253
gatcctgtg gctacgagtt cctgtggggg ccaagggccc ttgctgaaac cagctatgtg 1313
aaagtcctgg agcatgtggt caggggtcaat gcaagagttc gcatttccta cccatccctg 1373
catgaagagg ctttggggaga ggagaaagga gtttgagcag gagttgcagc tagggccagt 1433
ggggcaggtt gtgggagggc ctgggccagt gcacgttcca gggccacatc caccactttc 1493
cctgctctgt tacatgaggc ccattcttca ctctgtgttt gaagagagca gtcacagttc 1553
tcagttagtg ggagcatgtt ggggtgtgagg gaacacagtg tggaccatct ctcagttcct 1613
gttctatttg gcgatttgga ggtttatctt tgtttccttt tgggaattgtt ccaatgttcc 1673
ttctaattga tgggtgtaatg aacttcaaca ttcattttat gtatgacagt agacagactt 1733
actgcttttt atatagttta ggagtaagag tcttgctttt catttatact gggaaaccca 1793
tgttatttct tgaattc 1810

<210> 7
<211> 920
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (334)..(918)

<400> 7
acctgctcca ggacaaagtg gacccactg catcagctcc acctacccta ctgtcagtcc 60
tggagccttg gcctctgccg gctgcacctt gaggagccat ctctcacttc cttcttcagg 120
ttctcagggg acagggagag caagaggtca agagctgttg gacaccacag agcagcactg 180
aaggagaaga cctgtaagtt ggcctttgtt agaacctcca ggggtgtggt ctcagctgtg 240
gccacttaca cctccctctt ctccccaggc ctgtgggtcc ccatcgccca agtcctgccc 300

```

-12-

```

acactccac ctgctaccct gatcagagtc atc atg cct cga gct cca aag cgt 354
                               Met Pro Arg Ala Pro Lys Arg
                               1                               5

cag cgc tgc atg cct gaa gaa gat ctt caa tcc caa agt gag aca cag 402
Gln Arg Cys Met Pro Glu Glu Asp Leu Gln Ser Gln Ser Glu Thr Gln
          10                15                20

ggc ctc gag ggt gca cag gct ccc ctg gct gtg gag gag gat gct tca 450
Gly Leu Glu Gly Ala Gln Ala Pro Leu Ala Val Glu Glu Asp Ala Ser
          25                30                35

tca tcc act tcc acc agc tcc tct ttt cca tcc tct ttt ccc tcc tcc 498
Ser Ser Thr Ser Thr Ser Ser Ser Phe Pro Ser Ser Phe Pro Ser Ser
          40                45                50                55

tcc tct tcc tcc tcc tcc tcc tgc tat cct cta ata cca agc acc cca 546
Ser Ser Ser Ser Ser Ser Ser Cys Tyr Pro Leu Ile Pro Ser Thr Pro
          60                65                70

gag gag gtt tct gct gat gat gag aca cca aat cct ccc cag agt gct 594
Glu Glu Val Ser Ala Asp Asp Glu Thr Pro Asn Pro Pro Gln Ser Ala
          75                80                85

cag ata gcc tgc tcc tcc ccc tgc gtc gtt gct tcc ctt cca tta gat 642
Gln Ile Ala Cys Ser Ser Pro Ser Val Val Ala Ser Leu Pro Leu Asp
          90                95                100

caa tct gat gag ggc tcc agc agc caa aag gag gag agt cca agc acc 690
Gln Ser Asp Glu Gly Ser Ser Ser Gln Lys Glu Glu Ser Pro Ser Thr
          105                110                115

cta cag gtc ctg cca gac agt gag tct tta ccc aga agt gag ata gat 738
Leu Gln Val Leu Pro Asp Ser Glu Ser Leu Pro Arg Ser Glu Ile Asp
          120                125                130                135

gaa aag gtg act gat ttg gtg cag ttt ctg ctc ttc aag tat caa atg 786
Glu Lys Val Thr Asp Leu Val Gln Phe Leu Leu Phe Lys Tyr Gln Met
          140                145                150

aag gag ccg atc aca aag gca gaa ata ctg gag agt gtc ata aaa aat 834
Lys Glu Pro Ile Thr Lys Ala Glu Ile Leu Glu Ser Val Ile Lys Asn
          155                160                165

tat gaa gac cac ttc cct ttg ttg ttt agt gaa gcc tcc gag tgc atg 882
Tyr Glu Asp His Phe Pro Leu Leu Phe Ser Glu Ala Ser Glu Cys Met
          170                175                180

ctg ctg gtc ttt ggc att gat gta aag gaa gtg gat cc 920
Leu Leu Val Phe Gly Ile Asp Val Lys Glu Val Asp
          185                190                195

```

-13-

<210> 8  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 8  
Glu Ala Asp Pro Thr Gly His Ser Tyr  
1 5

<210> 9  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 9  
Ser Ala Tyr Gly Glu Pro Arg Lys Leu  
1 5

<210> 10  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 10  
Glu Val Asp Pro Ile Gly His Leu Tyr  
1 5

<210> 11  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 11  
Phe Leu Trp Gly Pro Arg Ala Leu Val  
1 5

<210> 12  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 12  
Met Glu Val Asp Pro Ile Gly His Leu Tyr  
1 5 10

<210> 13  
<211> 9  
<212> PRT  
<213> Homo sapiens



-14-

<400> 13  
Ala Ala Arg Ala Val Phe Leu Ala Leu  
1 5

<210> 14  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 14  
Tyr Arg Pro Arg Pro Arg Arg Tyr  
1 5

<210> 15  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 15  
Ser Pro Ser Ser Asn Arg Ile Arg Asn Thr  
1 5 10

<210> 16  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 16  
Val Leu Pro Asp Val Phe Ile Arg Cys  
1 5

<210> 17  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 17  
Val Leu Pro Asp Val Phe Ile Arg Cys Val  
1 5 10

<210> 18  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 18  
Glu Glu Lys Leu Ile Val Val Leu Phe  
1 5

-15-

<210> 19  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 19  
Glu Glu Lys Leu Ser Val Val Leu Phe  
1 5

<210> 20  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 20  
Ala Cys Asp Pro His Ser Gly His Phe Val  
1 5 10

<210> 21  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 21  
Ala Arg Asp Pro His Ser Gly His Phe Val  
1 5 10

<210> 22  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 22  
Ser Tyr Leu Asp Ser Gly Ile His Phe  
1 5

<210> 23  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 23  
Ser Tyr Leu Asp Ser Gly Ile His Ser  
1 5

<210> 24  
<211> 9

-16-

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 24

Met Leu Leu Ala Val Leu Tyr Cys Leu  
1 5

&lt;210&gt; 25

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 25

Tyr Met Asn Gly Thr Met Ser Gln Val  
1 5

&lt;210&gt; 26

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 26

Ala Phe Leu Pro Trp His Arg Leu Phe  
1 5

&lt;210&gt; 27

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 27

Ser Glu Ile Trp Arg Asp Ile Asp Phe  
1 5

&lt;210&gt; 28

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 28

Tyr Glu Ile Trp Arg Asp Ile Asp Phe  
1 5

&lt;210&gt; 29

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

-17-

&lt;400&gt; 29

Gln Asn Ile Leu Leu Ser Asn Ala Pro Leu Gly Pro Gln Phe Pro  
1 5 10 15

&lt;210&gt; 30

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 30

Asp Tyr Ser Tyr Leu Gln Asp Ser Asp Pro Asp Ser Phe Gln Asp  
1 5 10 15

&lt;210&gt; 31

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 31

Ala Ala Gly Ile Gly Ile Leu Thr Val  
1 5

&lt;210&gt; 32

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 32

Glu Ala Ala Gly Ile Gly Ile Leu Thr Val  
1 5 10

&lt;210&gt; 33

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 33

Ile Leu Thr Val Ile Leu Gly Val Leu  
1 5

&lt;210&gt; 34

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 34

Lys Thr Trp Gly Gln Tyr Trp Gln Val  
1 5

-18-

<210> 35  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 35  
Ile Thr Asp Gln Val Pro Phe Ser Val  
1 5

<210> 36  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 36  
Tyr Leu Glu Pro Gly Pro Val Thr Ala  
1 5

<210> 37  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 37  
Leu Leu Asp Gly Thr Ala Thr Leu Arg Leu  
1 5 10

<210> 38  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 38  
Val Leu Tyr Arg Tyr Gly Ser Phe Ser Val  
1 5 10

<210> 39  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 39  
Leu Tyr Val Asp Ser Leu Phe Phe Leu  
1 5

<210> 40  
<211> 12  
<212> PRT

-19-

&lt;213&gt; Homo sapiens

&lt;400&gt; 40

Lys Ile Ser Gly Gly Pro Arg Ile Ser Tyr Pro Leu  
1 5 10

&lt;210&gt; 41

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 41

Tyr Met Asp Gly Thr Met Ser Gln Val  
1 5

&lt;210&gt; 42

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 42

Gly Leu Tyr Asp Gly Met Glu His Leu  
1 5

&lt;210&gt; 43

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 43

Gly Leu Tyr Asp Gly Arg Glu His Ser  
1 5

&lt;210&gt; 44

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 44

Gly Leu Tyr Asp Gly Met Glu His Leu Ile  
1 5 10

&lt;210&gt; 45

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

-20-

<400> 45  
Gly Leu Tyr Asp Gly Arg Glu His Ser Val  
1 5 10

<210> 46  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 46  
Met Leu Leu Val Phe Gly Ile Asp Val  
1 5

<210> 47  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 47  
Cys Met Leu Leu Val Phe Gly Ile Asp Val  
1 5 10

<210> 48  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 48  
Phe Leu Leu Phe Lys Tyr Gln Met Lys  
1 5

<210> 49  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 49  
Phe Ile Glu Gly Tyr Cys Thr Pro Glu  
1 5

<210> 50  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 50  
Gly Leu Glu Leu Ala Gln Ala Pro Leu  
1 5

-21-

<210> 51  
<211> 29  
<212> DNA  
<213> Homo sapiens

<400> 51  
ggaattcatc atgcctcgag ctccaaagc

29

<210> 52  
<211> 31  
<212> DNA  
<213> Homo sapiens

<400> 52  
gctctagagc ttaggctatc tgagcactct g

31

<210> 53  
<211> 31  
<212> DNA  
<213> Homo sapiens

<400> 53  
gctctagagc ttagcactcg gaggcttcac t

31

<210> 54  
<211> 31  
<212> DNA  
<213> Homo sapiens

<400> 54  
gctctagagc ttaccaatct tgggtgagca g

31

<210> 55  
<211> 21  
<212> DNA  
<213> Homo sapiens

<400> 55  
cacagagcag cactgaagga g

21

<210> 56  
<211> 23  
<212> DNA  
<213> Homo sapiens

<400> 56  
ctgggtaaag actcactgtc tgg

23